CN1579485A - Traditional Chinese medicinal composition for treating intestinal function disorder and its preparation method - Google Patents
Traditional Chinese medicinal composition for treating intestinal function disorder and its preparation method Download PDFInfo
- Publication number
- CN1579485A CN1579485A CN200410014337.4A CN200410014337A CN1579485A CN 1579485 A CN1579485 A CN 1579485A CN 200410014337 A CN200410014337 A CN 200410014337A CN 1579485 A CN1579485 A CN 1579485A
- Authority
- CN
- China
- Prior art keywords
- grams
- radix
- extract
- chinese medicine
- component
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims description 171
- 238000002360 preparation method Methods 0.000 title claims description 33
- 230000003871 intestinal function Effects 0.000 title description 3
- 239000000284 extract Substances 0.000 claims abstract description 135
- 239000003814 drug Substances 0.000 claims abstract description 92
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 48
- 150000001875 compounds Chemical class 0.000 claims abstract description 42
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 36
- 239000011347 resin Substances 0.000 claims abstract description 25
- 229920005989 resin Polymers 0.000 claims abstract description 25
- 238000000034 method Methods 0.000 claims abstract description 21
- 239000000341 volatile oil Substances 0.000 claims abstract description 13
- 229920000858 Cyclodextrin Polymers 0.000 claims abstract description 12
- 239000007788 liquid Substances 0.000 claims abstract description 11
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims abstract description 11
- 238000000605 extraction Methods 0.000 claims abstract description 10
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 claims description 83
- 208000014540 Functional gastrointestinal disease Diseases 0.000 claims description 20
- 201000007637 bowel dysfunction Diseases 0.000 claims description 20
- 238000003809 water extraction Methods 0.000 claims description 18
- 238000010521 absorption reaction Methods 0.000 claims description 17
- 239000010135 fructus aurantii immaturus Substances 0.000 claims description 16
- 238000000703 high-speed centrifugation Methods 0.000 claims description 16
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims description 15
- 239000003960 organic solvent Substances 0.000 claims description 15
- 239000000126 substance Substances 0.000 claims description 15
- 239000000470 constituent Substances 0.000 claims description 13
- 238000000638 solvent extraction Methods 0.000 claims description 13
- FLZQKRKHLSUHOR-UHFFFAOYSA-N alosetron Chemical compound CC1=NC=N[C]1CN1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FLZQKRKHLSUHOR-UHFFFAOYSA-N 0.000 claims description 12
- 229960003550 alosetron Drugs 0.000 claims description 12
- 238000012869 ethanol precipitation Methods 0.000 claims description 11
- 239000008187 granular material Substances 0.000 claims description 9
- 239000002775 capsule Substances 0.000 claims description 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 8
- 239000002994 raw material Substances 0.000 claims description 8
- 239000006228 supernatant Substances 0.000 claims description 8
- 239000000829 suppository Substances 0.000 claims description 8
- 239000003826 tablet Substances 0.000 claims description 8
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims description 6
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims description 6
- 239000000796 flavoring agent Substances 0.000 claims description 6
- 235000019634 flavors Nutrition 0.000 claims description 6
- 229910021647 smectite Inorganic materials 0.000 claims description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 5
- DCSUBABJRXZOMT-IRLDBZIGSA-N cisapride Chemical compound C([C@@H]([C@@H](CC1)NC(=O)C=2C(=CC(N)=C(Cl)C=2)OC)OC)N1CCCOC1=CC=C(F)C=C1 DCSUBABJRXZOMT-IRLDBZIGSA-N 0.000 claims description 5
- 229960005132 cisapride Drugs 0.000 claims description 5
- DCSUBABJRXZOMT-UHFFFAOYSA-N cisapride Natural products C1CC(NC(=O)C=2C(=CC(N)=C(Cl)C=2)OC)C(OC)CN1CCCOC1=CC=C(F)C=C1 DCSUBABJRXZOMT-UHFFFAOYSA-N 0.000 claims description 5
- 229960001253 domperidone Drugs 0.000 claims description 5
- FGXWKSZFVQUSTL-UHFFFAOYSA-N domperidone Chemical compound C12=CC=CC=C2NC(=O)N1CCCN(CC1)CCC1N1C2=CC=C(Cl)C=C2NC1=O FGXWKSZFVQUSTL-UHFFFAOYSA-N 0.000 claims description 5
- VWZPIJGXYWHBOW-UHFFFAOYSA-N otilonium bromide Chemical compound [Br-].CCCCCCCCOC1=CC=CC=C1C(=O)NC1=CC=C(C(=O)OCC[N+](C)(CC)CC)C=C1 VWZPIJGXYWHBOW-UHFFFAOYSA-N 0.000 claims description 5
- 239000000741 silica gel Substances 0.000 claims description 5
- 229910002027 silica gel Inorganic materials 0.000 claims description 5
- 229960001866 silicon dioxide Drugs 0.000 claims description 5
- 229960005345 trimebutine Drugs 0.000 claims description 5
- 238000004587 chromatography analysis Methods 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 241000894006 Bacteria Species 0.000 claims description 3
- FSRLGULMGJGKGI-BTJKTKAUSA-N Trimebutine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=CC=1C(CC)(N(C)C)COC(=O)C1=CC(OC)=C(OC)C(OC)=C1 FSRLGULMGJGKGI-BTJKTKAUSA-N 0.000 claims description 3
- IKGXLCMLVINENI-QOXGANSBSA-M [Br-].COc1cc(Br)c(C[N+]2(CCOCC[C@@H]3CC[C@H]4C[C@@H]3C4(C)C)CCOCC2)cc1OC Chemical compound [Br-].COc1cc(Br)c(C[N+]2(CCOCC[C@@H]3CC[C@H]4C[C@@H]3C4(C)C)CCOCC2)cc1OC IKGXLCMLVINENI-QOXGANSBSA-M 0.000 claims description 3
- 239000003463 adsorbent Substances 0.000 claims description 3
- 238000005342 ion exchange Methods 0.000 claims description 3
- 229960000426 otilonium bromide Drugs 0.000 claims description 3
- 229960002088 pinaverium bromide Drugs 0.000 claims description 3
- 229930192474 thiophene Natural products 0.000 claims description 3
- 238000002481 ethanol extraction Methods 0.000 claims description 2
- 230000000712 assembly Effects 0.000 claims 1
- 238000000429 assembly Methods 0.000 claims 1
- 229940079593 drug Drugs 0.000 abstract description 15
- -1 shimida Chemical class 0.000 abstract description 9
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 abstract description 5
- 238000004519 manufacturing process Methods 0.000 abstract description 5
- 230000008569 process Effects 0.000 abstract description 4
- 241000132012 Atractylodes Species 0.000 abstract description 3
- 230000006870 function Effects 0.000 abstract description 3
- 210000000936 intestine Anatomy 0.000 abstract description 2
- 239000004615 ingredient Substances 0.000 abstract 2
- 241000094396 Bolitoglossa carri Species 0.000 abstract 1
- 241000202726 Bupleurum Species 0.000 abstract 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 abstract 1
- 244000303040 Glycyrrhiza glabra Species 0.000 abstract 1
- 244000236658 Paeonia lactiflora Species 0.000 abstract 1
- 235000008598 Paeonia lactiflora Nutrition 0.000 abstract 1
- 235000001188 Peltandra virginica Nutrition 0.000 abstract 1
- 244000197580 Poria cocos Species 0.000 abstract 1
- 235000008599 Poria cocos Nutrition 0.000 abstract 1
- 241001038563 Pseudostellaria Species 0.000 abstract 1
- 244000046146 Pueraria lobata Species 0.000 abstract 1
- 235000010575 Pueraria lobata Nutrition 0.000 abstract 1
- 241000157352 Uncaria Species 0.000 abstract 1
- 238000000151 deposition Methods 0.000 abstract 1
- 235000011477 liquorice Nutrition 0.000 abstract 1
- 238000004806 packaging method and process Methods 0.000 abstract 1
- 210000000952 spleen Anatomy 0.000 description 40
- 241000699670 Mus sp. Species 0.000 description 34
- 206010012735 Diarrhoea Diseases 0.000 description 29
- 210000001541 thymus gland Anatomy 0.000 description 29
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 27
- 210000004877 mucosa Anatomy 0.000 description 26
- 230000037396 body weight Effects 0.000 description 25
- 238000002474 experimental method Methods 0.000 description 23
- 230000000968 intestinal effect Effects 0.000 description 23
- 235000013305 food Nutrition 0.000 description 22
- 239000007787 solid Substances 0.000 description 22
- 206010010774 Constipation Diseases 0.000 description 21
- DNXIKVLOVZVMQF-UHFFFAOYSA-N (3beta,16beta,17alpha,18beta,20alpha)-17-hydroxy-11-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-yohimban-16-carboxylic acid, methyl ester Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(O)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 DNXIKVLOVZVMQF-UHFFFAOYSA-N 0.000 description 20
- LCQMZZCPPSWADO-UHFFFAOYSA-N Reserpilin Natural products COC(=O)C1COCC2CN3CCc4c([nH]c5cc(OC)c(OC)cc45)C3CC12 LCQMZZCPPSWADO-UHFFFAOYSA-N 0.000 description 20
- QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 description 20
- 210000001630 jejunum Anatomy 0.000 description 20
- 210000002381 plasma Anatomy 0.000 description 20
- BJOIZNZVOZKDIG-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C([C]5C=CC(OC)=CC5=N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 BJOIZNZVOZKDIG-MDEJGZGSSA-N 0.000 description 20
- 229960003147 reserpine Drugs 0.000 description 20
- MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 description 20
- 210000001519 tissue Anatomy 0.000 description 20
- 241000699666 Mus <mouse, genus> Species 0.000 description 19
- 238000004458 analytical method Methods 0.000 description 18
- 230000007812 deficiency Effects 0.000 description 18
- 238000004128 high performance liquid chromatography Methods 0.000 description 18
- 210000000813 small intestine Anatomy 0.000 description 18
- 210000002919 epithelial cell Anatomy 0.000 description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 16
- 208000002551 irritable bowel syndrome Diseases 0.000 description 16
- 229930003347 Atropine Natural products 0.000 description 15
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 15
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 15
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 15
- 229960000396 atropine Drugs 0.000 description 15
- ALWKGYPQUAPLQC-UHFFFAOYSA-N neostigmine Chemical compound CN(C)C(=O)OC1=CC=CC([N+](C)(C)C)=C1 ALWKGYPQUAPLQC-UHFFFAOYSA-N 0.000 description 15
- 229960002362 neostigmine Drugs 0.000 description 15
- 208000024891 symptom Diseases 0.000 description 14
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 13
- 230000000694 effects Effects 0.000 description 13
- 206010000087 Abdominal pain upper Diseases 0.000 description 12
- 230000006378 damage Effects 0.000 description 11
- 210000001035 gastrointestinal tract Anatomy 0.000 description 11
- 239000012567 medical material Substances 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 201000010099 disease Diseases 0.000 description 10
- 230000004064 dysfunction Effects 0.000 description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- 208000027418 Wounds and injury Diseases 0.000 description 8
- 208000014674 injury Diseases 0.000 description 8
- 238000001256 steam distillation Methods 0.000 description 8
- 230000013872 defecation Effects 0.000 description 7
- 230000000857 drug effect Effects 0.000 description 7
- 230000002496 gastric effect Effects 0.000 description 6
- JBQATDIMBVLPRB-UHFFFAOYSA-N isoliquiritigenin Natural products OC1=CC(O)=CC=C1C1OC2=CC(O)=CC=C2C(=O)C1 JBQATDIMBVLPRB-UHFFFAOYSA-N 0.000 description 6
- IYRMWMYZSQPJKC-UHFFFAOYSA-N kaempferol Chemical compound C1=CC(O)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 IYRMWMYZSQPJKC-UHFFFAOYSA-N 0.000 description 6
- 238000001291 vacuum drying Methods 0.000 description 6
- 208000019790 abdominal distention Diseases 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 229930182470 glycoside Natural products 0.000 description 5
- 239000000955 prescription drug Substances 0.000 description 5
- 238000001694 spray drying Methods 0.000 description 5
- TYPSVDGIQAOBAD-DZGCQCFKSA-N Atractylone Chemical compound C([C@]1(C)C2)CCC(=C)[C@@H]1CC1=C2OC=C1C TYPSVDGIQAOBAD-DZGCQCFKSA-N 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 4
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 238000013019 agitation Methods 0.000 description 4
- 230000001476 alcoholic effect Effects 0.000 description 4
- 239000006286 aqueous extract Substances 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- LQGUBLBATBMXHT-UHFFFAOYSA-N chrysophanol Chemical compound C1=CC=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O LQGUBLBATBMXHT-UHFFFAOYSA-N 0.000 description 4
- 230000003203 everyday effect Effects 0.000 description 4
- 230000007661 gastrointestinal function Effects 0.000 description 4
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 4
- 229960004949 glycyrrhizic acid Drugs 0.000 description 4
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 4
- 235000019410 glycyrrhizin Nutrition 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- DXDRHHKMWQZJHT-FPYGCLRLSA-N isoliquiritigenin Chemical compound C1=CC(O)=CC=C1\C=C\C(=O)C1=CC=C(O)C=C1O DXDRHHKMWQZJHT-FPYGCLRLSA-N 0.000 description 4
- 235000008718 isoliquiritigenin Nutrition 0.000 description 4
- 230000003340 mental effect Effects 0.000 description 4
- 230000036407 pain Effects 0.000 description 4
- KFUCYPGCMLPUMT-UHFFFAOYSA-N perlolyrine Chemical compound O1C(CO)=CC=C1C1=NC=CC2=C1NC1=CC=CC=C21 KFUCYPGCMLPUMT-UHFFFAOYSA-N 0.000 description 4
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 3
- 239000004378 Glycyrrhizin Substances 0.000 description 3
- YKRGDOXKVOZESV-WRJNSLSBSA-N Paeoniflorin Chemical compound C([C@]12[C@H]3O[C@]4(O)C[C@](O3)([C@]1(C[C@@H]42)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)C)OC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-WRJNSLSBSA-N 0.000 description 3
- 208000022531 anorexia Diseases 0.000 description 3
- TYPSVDGIQAOBAD-UHFFFAOYSA-N atractylone Natural products C1C2(C)CCCC(=C)C2CC2=C1OC=C2C TYPSVDGIQAOBAD-UHFFFAOYSA-N 0.000 description 3
- 238000009534 blood test Methods 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 206010061428 decreased appetite Diseases 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 239000003480 eluent Substances 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 150000002338 glycosides Chemical class 0.000 description 3
- YNWXJFQOCHMPCK-LXGDFETPSA-N isoliquiritin Chemical group O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C=C1)=CC=C1\C=C\C(=O)C1=CC=C(O)C=C1O YNWXJFQOCHMPCK-LXGDFETPSA-N 0.000 description 3
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 3
- 230000003908 liver function Effects 0.000 description 3
- YKRGDOXKVOZESV-UHFFFAOYSA-N paeoniflorin Natural products O1C(C)(C2(CC34)OC5C(C(O)C(O)C(CO)O5)O)CC3(O)OC1C24COC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-UHFFFAOYSA-N 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 238000010898 silica gel chromatography Methods 0.000 description 3
- GSZUGBAEBARHAW-UHFFFAOYSA-N sophoraflavone B Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(C=2OC3=CC(O)=CC=C3C(=O)C=2)C=C1 GSZUGBAEBARHAW-UHFFFAOYSA-N 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- IQVQXVFMNOFTMU-FLIBITNWSA-N (Z)-ligustilide Chemical compound C1CC=CC2=C1C(=C/CCC)/OC2=O IQVQXVFMNOFTMU-FLIBITNWSA-N 0.000 description 2
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 2
- LORDFXWUHHSAQU-UHFFFAOYSA-N 3,4,5-trimethoxybenzoic acid [2-(dimethylamino)-2-phenylbutyl] ester Chemical compound C=1C=CC=CC=1C(CC)(N(C)C)COC(=O)C1=CC(OC)=C(OC)C(OC)=C1 LORDFXWUHHSAQU-UHFFFAOYSA-N 0.000 description 2
- MJPMPMZXJIZPRE-UHFFFAOYSA-N 3-butyl-5,6,7,7a-tetrahydro-3h-2-benzofuran-1-one Chemical compound C1CCC=C2C(CCCC)OC(=O)C21 MJPMPMZXJIZPRE-UHFFFAOYSA-N 0.000 description 2
- LATYEZNGPQKAIK-UHFFFAOYSA-N 6'-O-benzoylpaeoniflorin Natural products O1C(C)(C2(CC34)OC5C(C(O)C(O)C(COC(=O)C=6C=CC=CC=6)O5)O)CC3(O)OC1C24COC(=O)C1=CC=CC=C1 LATYEZNGPQKAIK-UHFFFAOYSA-N 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- LATYEZNGPQKAIK-HRCYFWENSA-N Benzoylpaeoniflorin Chemical compound C([C@]12[C@H]3O[C@]4(O)C[C@](O3)([C@]1(C[C@@H]42)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](COC(=O)C=2C=CC=CC=2)O1)O)C)OC(=O)C1=CC=CC=C1 LATYEZNGPQKAIK-HRCYFWENSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 2
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 2
- YNWXJFQOCHMPCK-UHFFFAOYSA-N Isoliquiritin Natural products OC1C(O)C(O)C(CO)OC1OC(C=C1)=CC=C1C=CC(=O)C1=CC=C(O)C=C1O YNWXJFQOCHMPCK-UHFFFAOYSA-N 0.000 description 2
- GQODBWLKUWYOFX-UHFFFAOYSA-N Isorhamnetin Natural products C1=C(O)C(C)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 GQODBWLKUWYOFX-UHFFFAOYSA-N 0.000 description 2
- PUPKKEQDLNREIM-UHFFFAOYSA-N Kaempferitin Natural products OC1C(O)C(O)C(C)OC1OC1=CC(O)=C2C(=O)C(OC3C(C(O)C(O)C(C)O3)O)=C(C=3C=CC(O)=CC=3)OC2=C1 PUPKKEQDLNREIM-UHFFFAOYSA-N 0.000 description 2
- 238000012449 Kunming mouse Methods 0.000 description 2
- FURUXTVZLHCCNA-UHFFFAOYSA-N Liquiritigenin Natural products C1=CC(O)=CC=C1C1OC2=CC(O)=CC=C2C(=O)C1 FURUXTVZLHCCNA-UHFFFAOYSA-N 0.000 description 2
- DEMKZLAVQYISIA-UHFFFAOYSA-N Liquirtin Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(C2OC3=CC(O)=CC=C3C(=O)C2)C=C1 DEMKZLAVQYISIA-UHFFFAOYSA-N 0.000 description 2
- HJBUYKZTEBZNSH-ZRWXNEIDSA-N Neoliquiritin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(C(=O)C[C@H](O2)C=3C=CC(O)=CC=3)C2=C1 HJBUYKZTEBZNSH-ZRWXNEIDSA-N 0.000 description 2
- HJBUYKZTEBZNSH-ONJCETCRSA-N Neoliquiritin Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(C(=O)C[C@@H](O2)C=3C=CC(O)=CC=3)C2=C1 HJBUYKZTEBZNSH-ONJCETCRSA-N 0.000 description 2
- UILPJVPSNHJFIK-UHFFFAOYSA-N Paeonol Chemical compound COC1=CC=C(C(C)=O)C(O)=C1 UILPJVPSNHJFIK-UHFFFAOYSA-N 0.000 description 2
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 2
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 2
- 229930182883 Saikogenin Natural products 0.000 description 2
- KYWSCMDFVARMPN-LCSVLAELSA-N Saikosaponin D Chemical compound O([C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@]([C@H]3[C@]([C@@H]4[C@@]([C@@]5(C[C@@H](O)[C@]67CO[C@]5([C@@H]6CC(C)(C)CC7)C=C4)C)(C)CC3)(C)CC2)(C)CO)O[C@@H]([C@@H]1O)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O KYWSCMDFVARMPN-LCSVLAELSA-N 0.000 description 2
- FINHMKGKINIASC-UHFFFAOYSA-N Tetramethylpyrazine Chemical compound CC1=NC(C)=C(C)N=C1C FINHMKGKINIASC-UHFFFAOYSA-N 0.000 description 2
- KEIZXGINFPDITQ-UHFFFAOYSA-N UNPD138008 Natural products C1=C(O)C(OC)=CC=C1C1=C(OC2C(C(O)C(O)C(COC3C(C(O)C(O)C(C)O3)O)O2)O)C(=O)C2=C(O)C=C(O)C=C2O1 KEIZXGINFPDITQ-UHFFFAOYSA-N 0.000 description 2
- IQVQXVFMNOFTMU-DHZHZOJOSA-N Z-ligustilide Natural products C1CC=CC2=C1C(=C/CCC)\OC2=O IQVQXVFMNOFTMU-DHZHZOJOSA-N 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 206010000059 abdominal discomfort Diseases 0.000 description 2
- SOSLMHZOJATCCP-PADPQNGGSA-N afzelin Natural products O([C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](C)O1)C1=C(c2ccc(O)cc2)Oc2c(c(O)cc(O)c2)C1=O SOSLMHZOJATCCP-PADPQNGGSA-N 0.000 description 2
- VIWQCBZFJFSCLC-UHFFFAOYSA-N alpha-benzoyloxypaeoniflorin Natural products O1C(C)(C2(CC34)OC5C(C(O)C(O)C(COC(=O)C=6C=CC=CC=6)O5)O)CC3(O)OC1C24COC(=O)C1=CC=C(O)C=C1 VIWQCBZFJFSCLC-UHFFFAOYSA-N 0.000 description 2
- 230000036592 analgesia Effects 0.000 description 2
- 206010003549 asthenia Diseases 0.000 description 2
- NZPQWZZXRKZCDU-UHFFFAOYSA-N chrysophanol Natural products Cc1cc(O)c2C(=O)c3c(O)cccc3Oc2c1 NZPQWZZXRKZCDU-UHFFFAOYSA-N 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 229960003720 enoxolone Drugs 0.000 description 2
- 238000003810 ethyl acetate extraction Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- IZQSVPBOUDKVDZ-UHFFFAOYSA-N isorhamnetin Chemical compound C1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 IZQSVPBOUDKVDZ-UHFFFAOYSA-N 0.000 description 2
- 235000008800 isorhamnetin Nutrition 0.000 description 2
- UIDGLYUNOUKLBM-GEBJFKNCSA-N isorhamnetin-3-O-rutinoside Chemical compound C1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]3[C@@H]([C@H](O)[C@@H](O)[C@H](C)O3)O)O2)O)=C1 UIDGLYUNOUKLBM-GEBJFKNCSA-N 0.000 description 2
- BGLPQQKZNUKSAR-UHFFFAOYSA-N isorhamnetin-3-O-rutinoside Natural products COc1ccc(cc1O)C2=C(OC3OC(COCC4OC(O)C(O)C(O)C4O)C(O)C(O)C3O)C(=O)c5c(O)cc(O)cc5O2 BGLPQQKZNUKSAR-UHFFFAOYSA-N 0.000 description 2
- ZMGSKTZDVIZXJS-UHFFFAOYSA-N kaempferitrin Natural products CC1OC(OC2C(Oc3cc(OC4OC(C)C(O)C(O)C4O)cc(O)c3C2=O)c5ccc(O)cc5)C(O)C(O)C1O ZMGSKTZDVIZXJS-UHFFFAOYSA-N 0.000 description 2
- PUPKKEQDLNREIM-QNSQPKOQSA-N kaempferol 3,7-di-O-alpha-L-rhamnoside Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC1=CC(O)=C2C(=O)C(O[C@H]3[C@@H]([C@H](O)[C@@H](O)[C@H](C)O3)O)=C(C=3C=CC(O)=CC=3)OC2=C1 PUPKKEQDLNREIM-QNSQPKOQSA-N 0.000 description 2
- 150000002596 lactones Chemical class 0.000 description 2
- FURUXTVZLHCCNA-AWEZNQCLSA-N liquiritigenin Chemical compound C1=CC(O)=CC=C1[C@H]1OC2=CC(O)=CC=C2C(=O)C1 FURUXTVZLHCCNA-AWEZNQCLSA-N 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- IEPKWJCBNGNVDF-UHFFFAOYSA-N narcissin Natural products OC1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)OC2C(C(O)C(O)C(COC3C(C(O)C(O)C(C)O3)O)O2)O)=C1 IEPKWJCBNGNVDF-UHFFFAOYSA-N 0.000 description 2
- 239000009835 oxypaeoniflora Substances 0.000 description 2
- FCHVXNVDFYXLIL-QYDSDWLYSA-N oxypaeoniflorin Chemical compound C([C@]12[C@H]3O[C@]4(O)C[C@](O3)([C@@]1(C[C@H]42)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)C)OC(=O)C1=CC=C(O)C=C1 FCHVXNVDFYXLIL-QYDSDWLYSA-N 0.000 description 2
- RLXWQODPAWIVOI-UHFFFAOYSA-N oxypaeoniflorin Natural products OCC1OC(OC23CC4C5(O)CC2OC(O5)C34COC(=O)c6ccc(O)cc6)C(O)C(O)C1O RLXWQODPAWIVOI-UHFFFAOYSA-N 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 235000005875 quercetin Nutrition 0.000 description 2
- 229960001285 quercetin Drugs 0.000 description 2
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 2
- 229960004555 rutoside Drugs 0.000 description 2
- 229930192014 saikosaponin Natural products 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- IKBKZGMPCYNSLU-RGVLZGJSSA-N tegaserod Chemical compound C1=C(OC)C=C2C(/C=N/NC(=N)NCCCCC)=CNC2=C1 IKBKZGMPCYNSLU-RGVLZGJSSA-N 0.000 description 2
- 229960002876 tegaserod Drugs 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- NLSMPWTZYGSAEU-CYUNEVMDSA-N (2s,3r,4s,5s,6r)-2-[7-hydroxy-2-(4-hydroxy-3-methoxyphenyl)-3-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxychromenylium-5-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol;chloride Chemical compound [Cl-].C1=C(O)C(OC)=CC(C=2C(=CC=3C(O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)=CC(O)=CC=3[O+]=2)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=C1 NLSMPWTZYGSAEU-CYUNEVMDSA-N 0.000 description 1
- SQEBMLCQNJOCBG-HVHJFMEUSA-N (5s)-3-(hydroxymethyl)-5-methoxy-4-methyl-5-[(e)-2-phenylethenyl]furan-2-one Chemical compound C=1C=CC=CC=1/C=C/[C@]1(OC)OC(=O)C(CO)=C1C SQEBMLCQNJOCBG-HVHJFMEUSA-N 0.000 description 1
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 description 1
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
- YNPUJIONBZSHJT-UHFFFAOYSA-N 2,3-trans-dihydro-3,5,4'-trihydroxyflavonol 7-O-alpha-L-rhamnoside Natural products OC1C(O)C(O)C(C)OC1OC1=CC(O)=C(C(=O)C(O)C(O2)C=3C=CC(O)=CC=3)C2=C1 YNPUJIONBZSHJT-UHFFFAOYSA-N 0.000 description 1
- OVSQVDMCBVZWGM-LQSBFMDOSA-N 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3-[(2r,3s,4r,5r,6s)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxychromen-4-one Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OVSQVDMCBVZWGM-LQSBFMDOSA-N 0.000 description 1
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 1
- HQNOUCSPWAGQND-GKLNBGJFSA-N 3,5-dihydroxy-2-(4-hydroxyphenyl)-7-[(2s,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxychromen-4-one Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC1=CC(O)=C2C(=O)C(O)=C(C=3C=CC(O)=CC=3)OC2=C1 HQNOUCSPWAGQND-GKLNBGJFSA-N 0.000 description 1
- YYGOPZCCRBWMBK-UHFFFAOYSA-N 3beta-Acetoxyatractylon Natural products C1C2C(=C)C(OC(=O)C)CCC2(C)CC2=C1C(C)=CO2 YYGOPZCCRBWMBK-UHFFFAOYSA-N 0.000 description 1
- KSDSYIXRWHRPMN-UHFFFAOYSA-N 4'-O-beta-D-Galactopyranoside-6''-p-Coumaroylprunin-4',5,7-Trihydroxyflavanone Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(C2OC3=CC(O)=CC(O)=C3C(=O)C2)C=C1 KSDSYIXRWHRPMN-UHFFFAOYSA-N 0.000 description 1
- SMRPGWBDLOQHOS-UHFFFAOYSA-N 5-[4,5-dihydroxy-6-(hydroxymethyl)-3-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxy-3,4-dihydroxy-6-[[9-hydroxy-4-(hydroxymethyl)-4,6a,6b,8a,11,11,14b-heptamethyl-14-oxo-2,3,4a,5,6,7,8,9,10,12,12a,14a-dodecahydro-1H-picen-3-yl]oxy]oxane-2-carboxylic acid Chemical compound OC1C(O)C(O)C(C)OC1OC1C(OC2C(OC(C(O)C2O)C(O)=O)OC2C(C3C(C4C(C5(CCC6(C)C(O)CC(C)(C)CC6C5=CC4=O)C)(C)CC3)(C)CC2)(C)CO)OC(CO)C(O)C1O SMRPGWBDLOQHOS-UHFFFAOYSA-N 0.000 description 1
- HOMSOWZTBJWNHP-UHFFFAOYSA-N 5-chlorothiadiazole Chemical compound ClC1=CN=NS1 HOMSOWZTBJWNHP-UHFFFAOYSA-N 0.000 description 1
- LVRVABPNVHYXRT-BQWXUCBYSA-N 52906-92-0 Chemical compound C([C@H](N)C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(O)=O)C(C)C)C1=CC=CC=C1 LVRVABPNVHYXRT-BQWXUCBYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- IRLNKOAURQPXIQ-WWWUCTDISA-N Apiopaeonoside Natural products O=C(C)c1c(O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO[C@H]3[C@H](O)[C@@](O)(CO)CO3)O2)cc(OC)cc1 IRLNKOAURQPXIQ-WWWUCTDISA-N 0.000 description 1
- 240000007087 Apium graveolens Species 0.000 description 1
- 235000015849 Apium graveolens Dulce Group Nutrition 0.000 description 1
- 235000010591 Appio Nutrition 0.000 description 1
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- MPUFGOPEVKRAGE-UHFFFAOYSA-N Chuanxiongol Natural products C1=CC(O)=C2C(=CCCC)OCC(=O)C2=C1 MPUFGOPEVKRAGE-UHFFFAOYSA-N 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- FBMORZZOJSDNRQ-UHFFFAOYSA-N Demethoxy,B,HCl-Adriamycin Natural products C1C2C(=C)CCCC2(C)CC2(O)C1=C(C)C(=O)O2 FBMORZZOJSDNRQ-UHFFFAOYSA-N 0.000 description 1
- UBSCDKPKWHYZNX-UHFFFAOYSA-N Demethoxycapillarisin Natural products C1=CC(O)=CC=C1OC1=CC(=O)C2=C(O)C=C(O)C=C2O1 UBSCDKPKWHYZNX-UHFFFAOYSA-N 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- 239000001116 FEMA 4028 Substances 0.000 description 1
- 206010067715 Gastrointestinal sounds abnormal Diseases 0.000 description 1
- 240000002045 Guettarda speciosa Species 0.000 description 1
- 235000001287 Guettarda speciosa Nutrition 0.000 description 1
- LAHSXXNOJMWHBH-WVPBMNGESA-N Gypsoside Natural products O=C(O)[C@H]1[C@H](O[C@H]2[C@@H](O)[C@H](O)[C@H](O[C@@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)[C@H](CO)O2)[C@H](O[C@H]2[C@@H](O)[C@@H](O)[C@@H](O)CO2)[C@@H](O)[C@@H](O[C@@H]2[C@](C=O)(C)[C@@H]3[C@](C)([C@H]4[C@](C)([C@]5(C)C([C@H]6[C@](C(=O)O[C@H]7[C@H](O[C@@H]8[C@H](O[C@@H]9[C@H](O)[C@H](O)[C@H](O)CO9)[C@H](O)[C@H](O)CO8)[C@@H](O)[C@@H](O[C@@H]8[C@@H](O)[C@@H](O[C@H]9[C@@H](O)[C@@H](O)[C@@H](O)CO9)[C@H](O)[C@@H](C)O8)[C@@H](C)O7)(CC5)CCC(C)(C)C6)=CC4)CC3)CC2)O1 LAHSXXNOJMWHBH-WVPBMNGESA-N 0.000 description 1
- OVSQVDMCBVZWGM-IDRAQACASA-N Hirsutrin Natural products O([C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1)C1=C(c2cc(O)c(O)cc2)Oc2c(c(O)cc(O)c2)C1=O OVSQVDMCBVZWGM-IDRAQACASA-N 0.000 description 1
- 239000009636 Huang Qi Substances 0.000 description 1
- FVQOMEDMFUMIMO-UHFFFAOYSA-N Hyperosid Natural products OC1C(O)C(O)C(CO)OC1OC1C(=O)C2=C(O)C=C(O)C=C2OC1C1=CC=C(O)C(O)=C1 FVQOMEDMFUMIMO-UHFFFAOYSA-N 0.000 description 1
- 206010065952 Hyperpathia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- OBPMSXUPNDBUII-UHFFFAOYSA-N Kaempferol 7-O-alpha-L-rhamnopyranoside Natural products CC1C(O)C(O)OC(Oc2cc(O)c3C(=O)C(=C(Oc3c2)c4ccc(O)cc4)O)C1O OBPMSXUPNDBUII-UHFFFAOYSA-N 0.000 description 1
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 description 1
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 1
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 1
- DEMKZLAVQYISIA-ONJCETCRSA-N Liquiritin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)c1ccc([C@@H]2Oc3c(C(=O)C2)ccc(O)c3)cc1 DEMKZLAVQYISIA-ONJCETCRSA-N 0.000 description 1
- 102000002419 Motilin Human genes 0.000 description 1
- 101800002372 Motilin Proteins 0.000 description 1
- 206010028140 Mucous stools Diseases 0.000 description 1
- 206010029333 Neurosis Diseases 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 244000170916 Paeonia officinalis Species 0.000 description 1
- 235000006484 Paeonia officinalis Nutrition 0.000 description 1
- IDZZECHGWAZTIB-NYBIBFQCSA-N Paeonolide Chemical compound COC1=CC=C(C(C)=O)C(O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]3[C@@H]([C@@H](O)[C@@H](O)CO3)O)O2)O)=C1 IDZZECHGWAZTIB-NYBIBFQCSA-N 0.000 description 1
- IDZZECHGWAZTIB-WPQJODJHSA-N Paeonolide Natural products O=C(C)c1c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]3[C@@H](O)[C@H](O)[C@@H](O)CO3)O2)cc(OC)cc1 IDZZECHGWAZTIB-WPQJODJHSA-N 0.000 description 1
- AVIUTYMRHHBXPB-UXXRCYHCSA-N Paeonoside Natural products COC1=CC=C(C(C)=O)C(O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=C1 AVIUTYMRHHBXPB-UXXRCYHCSA-N 0.000 description 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 206010034719 Personality change Diseases 0.000 description 1
- 208000035755 Psychosomatic disease Diseases 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 238000010266 Sephadex chromatography Methods 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 208000024799 Thyroid disease Diseases 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- NKGSEACIYQINQJ-UHFFFAOYSA-N Ventricosin A Natural products C=C1CCCC2(C)CC(=O)C(=C(C)C)CC21 NKGSEACIYQINQJ-UHFFFAOYSA-N 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 102000011759 adducin Human genes 0.000 description 1
- 108010076723 adducin Proteins 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- IDZZECHGWAZTIB-UHFFFAOYSA-N affinoside Natural products COC1=CC=C(C(C)=O)C(OC2C(C(O)C(O)C(COC3C(C(O)C(O)CO3)O)O2)O)=C1 IDZZECHGWAZTIB-UHFFFAOYSA-N 0.000 description 1
- IAJILQKETJEXLJ-RSJOWCBRSA-N aldehydo-D-galacturonic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-RSJOWCBRSA-N 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- HQNOUCSPWAGQND-UHFFFAOYSA-N alpha-Rhamnoisorobin Natural products OC1C(O)C(O)C(C)OC1OC1=CC(O)=C2C(=O)C(O)=C(C=3C=CC(O)=CC=3)OC2=C1 HQNOUCSPWAGQND-UHFFFAOYSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 239000003957 anion exchange resin Substances 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- TYPSVDGIQAOBAD-HIFRSBDPSA-N atractylon Natural products Cc1coc2C[C@]3(C)CCCC(=C)[C@H]3Cc12 TYPSVDGIQAOBAD-HIFRSBDPSA-N 0.000 description 1
- 229910052788 barium Inorganic materials 0.000 description 1
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 1
- 229960004853 betadex Drugs 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000002021 butanolic extract Substances 0.000 description 1
- 210000001217 buttock Anatomy 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000003729 cation exchange resin Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000003544 deproteinization Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- 239000002024 ethyl acetate extract Substances 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 description 1
- 229940114124 ferulic acid Drugs 0.000 description 1
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 description 1
- 235000001785 ferulic acid Nutrition 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 201000000117 functional diarrhea Diseases 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- AVIUTYMRHHBXPB-UHFFFAOYSA-N glucopaeonol Natural products COC1=CC=C(C(C)=O)C(OC2C(C(O)C(O)C(CO)O2)O)=C1 AVIUTYMRHHBXPB-UHFFFAOYSA-N 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 239000001685 glycyrrhizic acid Substances 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- YLTGFGDODHXMFB-UHFFFAOYSA-N isoacetovanillon Natural products COC1=CC=C(C(C)=O)C=C1O YLTGFGDODHXMFB-UHFFFAOYSA-N 0.000 description 1
- OVSQVDMCBVZWGM-QCKGUQPXSA-N isoquercetin Natural products OC[C@@H]1O[C@@H](OC2=C(Oc3cc(O)cc(O)c3C2=O)c4ccc(O)c(O)c4)[C@H](O)[C@@H](O)[C@@H]1O OVSQVDMCBVZWGM-QCKGUQPXSA-N 0.000 description 1
- 235000008777 kaempferol Nutrition 0.000 description 1
- XFFQVRFGLSBFON-DEFKTLOSSA-N kaempferol 3,7-di-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)=C(C=3C=CC(O)=CC=3)OC2=C1 XFFQVRFGLSBFON-DEFKTLOSSA-N 0.000 description 1
- JUTMAMXOAOYKHT-UHFFFAOYSA-N karrikinolide Natural products C1=COC=C2OC(=O)C(C)=C21 JUTMAMXOAOYKHT-UHFFFAOYSA-N 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- DEMKZLAVQYISIA-ZRWXNEIDSA-N liquiritin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C([C@H]2OC3=CC(O)=CC=C3C(=O)C2)C=C1 DEMKZLAVQYISIA-ZRWXNEIDSA-N 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- UXOUKMQIEVGVLY-UHFFFAOYSA-N morin Natural products OC1=CC(O)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UXOUKMQIEVGVLY-UHFFFAOYSA-N 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000015238 neurotic disease Diseases 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- VDYCLYGKCGVBHN-UHFFFAOYSA-N pachymaic acid Natural products CC12CCC(OC(C)=O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC(=C)C(C)C)C(O)=O)C(O)CC21C VDYCLYGKCGVBHN-UHFFFAOYSA-N 0.000 description 1
- SRDNLMOBFKJOSD-UHFFFAOYSA-N pachymic acid Natural products CC12CCC(OC(C)=O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C(O)=O)C(O)CC21C SRDNLMOBFKJOSD-UHFFFAOYSA-N 0.000 description 1
- 229930194807 paeonin Natural products 0.000 description 1
- MLIBGOFSXXWRIY-UHFFFAOYSA-N paeonol Natural products COC1=CC=C(O)C(C(C)=O)=C1 MLIBGOFSXXWRIY-UHFFFAOYSA-N 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 208000011906 peptic ulcer disease Diseases 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 210000001187 pylorus Anatomy 0.000 description 1
- OVSQVDMCBVZWGM-QSOFNFLRSA-N quercetin 3-O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OVSQVDMCBVZWGM-QSOFNFLRSA-N 0.000 description 1
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000002601 radiography Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 208000009146 rhinoscleroma Diseases 0.000 description 1
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 1
- 235000005493 rutin Nutrition 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- PPRSVUXPYPBULA-UHFFFAOYSA-N saponin A Natural products CC1(C)CCC2(CCC3(C)C(=CCC4C5(C)CCC(OC6OC(CO)C(O)C(O)C6=O)C(C)(C)C5CCC34C)C2C1)C(=O)O PPRSVUXPYPBULA-UHFFFAOYSA-N 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- WNIFXKPDILJURQ-UHFFFAOYSA-N stearyl glycyrrhizinate Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=O)OCCCCCCCCCCCCCCCCCC)(C)CC5C4=CC(=O)C3C21C WNIFXKPDILJURQ-UHFFFAOYSA-N 0.000 description 1
- 230000004206 stomach function Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 description 1
- 229940033123 tannic acid Drugs 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- DKVBOUDTNWVDEP-NJCHZNEYSA-N teicoplanin aglycone Chemical compound N([C@H](C(N[C@@H](C1=CC(O)=CC(O)=C1C=1C(O)=CC=C2C=1)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)OC=1C=C3C=C(C=1O)OC1=CC=C(C=C1Cl)C[C@H](C(=O)N1)NC([C@H](N)C=4C=C(O5)C(O)=CC=4)=O)C(=O)[C@@H]2NC(=O)[C@@H]3NC(=O)[C@@H]1C1=CC5=CC(O)=C1 DKVBOUDTNWVDEP-NJCHZNEYSA-N 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 208000021510 thyroid gland disease Diseases 0.000 description 1
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention is a Chinese traditional medicine compound for treating intestines functions disorder. The compound includes following ingredients: bupleurum root 6-18g, white peony root 6-30g, pseudostellaria root 3-18g, liquorice 6-15g. The method can be used in clinic directly without adding ingredients; it also can use the extract of above mentioned medicines as medicine; the extract is: a. extract the volatile oil for backup from above mentioned compound; b. carries on extraction with water, alcohol, or other organic solution to above mentioned volatile oil compound; c. purifies and separates: water extracting liquid, vacuum condensing, and alcohol depositing, resin absorbing and exchanging, high speed eccentric process, and cyclodextrin packaging method; d. the extracts in above steps are combined, and become medicine compound. There also can increase lagehead atractylodes, chuaniong rhizome, Tuckahoe, kudzu vine root, uncaria and other medicines; or some compounds such as shimida, and dopan ketone. The invention also provides a manufacturing method for above mentioned medicine.
Description
Technical field
The present invention relates to a kind of Chinese medicine compound compositions and modern preparation thereof for the treatment of the bowel dysfunction relevant disease, and the process for preparing this pharmaceutical composition.
Background technology
(irritable bowel syndrome is common digestive tract non-organic bowel dysfunction disease IBS) to irritable bowel syndrome, has the chronic clinical characters of outbreak repeatedly.Clinical symptoms show as abdominal discomfort (stomachache, abdominal distention) and intestinal movement unusual, changing (diarrhoea or constipation), stool character unusual (loose stool, Mucous Stool or scleroma are just), defecation frequency as bowl evacuation habit increases and is main performance, and continue to exist or intermittently outbreak, pathologic finding does not have specificity intestinal inflammatory lesion more, clinical diarrhea-type, constipation type, the alternate type of being divided into.Modern medicine thinks that pathogenic factor and Nervous and Mental Factors, the change of intestinal kinetics, eating and drinking without temperance, the colon secretion of IBS is relevant with absorption function change, alteration of intestinal flora etc., relate to biology and social mentality's factors such as (comprising intense strain, patient's personality and behavior) in its cause of disease and the morbidity, be acknowledged as a kind of psychosomatic disease.Treatment means is limited at present, how from lax intestinal smooth muscle, excitement and antagonism neurotransmitter, anxiety, acts on limited.And medicine usually is at disposing as single symptoms such as diarrhoea or constipation, mainly concentrate on adjusting, antidepressant, dynamics-promoting medicine treatment, calcium-channel antagonists and astringent treatment etc. to the intestinal microecology link, because the primary disease morbidity relates to spirit, diet, consitution many aspects, though above various kinds of drug can be alleviated some symptom of irritable bowel syndrome, in clinical practice, all there are one-sidedness and limitation, still can not satisfy clinical requirement.But in application, exist can't effect a radical cure, shortcomings such as side effect is big, individual variation is obvious, medical expense height.
03112782.7 number Chinese invention patent application discloses a kind of " Chinese medicine composition and the preparation thereof of treatment bowel dysfunction disease ", this scheme thinks that Nervous and Mental Factors is the primary cause of disease of bowel dysfunction, should provide following prescription with the principle of " organic conception " and " determination of treatment based on pathogenesis obtained through differentiation of symptoms and signs ": Radix Bupleuri 6-15 gram, Radix Paeoniae Alba 5-20 gram, Rhizoma Chuanxiong-10 gram, Rhizoma Atractylodis Macrocephalae 6-20 gram, Poria 6-12 gram, Radix Glycyrrhizae 5-20 gram.The conception of this scheme and effect all are suitable for clinical practice, but rule of thumb, and Producer can wish this scheme is further simplified mostly, so as more to be suitable for industrialized great production prescription scheme and production technology.
Summary of the invention
Multifactor in comprehensively comprehensive this symptom grouping pathogeny of the present invention, and the Chinese medicine compound compositions of the treatment irritable bowel syndrome bowel dysfunction diseases such as (IBS) that provides.The clinical main performance diarrhoea of IBS, constipation, stomachache, alternating diarrhea and constipation; Companion anorexia, asthenia, poor, the agitation of becoming thin, sleep etc.Modern medicine is divided into diarrhea-type, constipation type, alternate type.This project inventor from theory of Chinese medical science, thinks that the common and primary reason of IBS is a Nervous and Mental Factors on the basis of clinical treatment and scientific research for many years.Patient is psychentonia, depression, morbidity or increase the weight of when irritated often, belongs to the traditional Chinese medical science " seven emotions " category that causes a disease, and sums up relevant Therapeutic Principle and square substantially through clinical verification on this basis.
The Chinese medicine composition of above-mentioned treatment bowel dysfunction comprises:
Radix Bupleuri 6-18 gram,
Radix Paeoniae Alba 6-30 gram,
Radix Pseudostellariae 6-18 gram,
Radix Glycyrrhizae 6-15 gram.
More than the used proportional quantities in basic side for alleviating, alleviate or cure relevant indication, regulate the various medical material amounts of intestines and stomach function and the ratio of drug regimen.Emergency weight according to clinical symptoms can adopt following ratio.
Basic side optimizes consumption 1:
Radix Bupleuri 12-18 gram,
Radix Paeoniae Alba 12-30 gram,
Radix Pseudostellariae 6-12 gram,
Radix Glycyrrhizae 6-12 gram.
Basic side optimizes consumption 2:
Radix Bupleuri 9-12 gram,
Radix Paeoniae Alba 9-12 gram,
Radix Pseudostellariae 6-12 gram,
Radix Glycyrrhizae 6-12 gram.
Below substantially can be so that following several embodiment to be arranged:
1, do not add any component, directly in clinical use: said composition is prescription;
2, with the extract of above-mentioned Chinese medicine composition as medicine;
3, on above-mentioned basic side's basis, increase other composition;
4, on the basis of the extract of above-mentioned Chinese medicine composition, increase other composition.
Above 2,3,4 are respectively described below:
Wherein " with the extract of above-mentioned Chinese medicine composition as medicine ", said " extract " is meant:
A, extraction volatile oil for backup from above mentioned compound;
B, the compositions behind the said extracted volatile oil is adopted water, ethanol or other organic solvent extraction;
Compositions behind c, water, ethanol or other organic solvent extraction adopts vacuum concentration, ethanol precipitation, resin absorption, resins exchange, the extract that technical method alone or in combination such as high speed centrifugation, cyclodextrin inclusion compound etc. obtains;
D, the extract of above steps is merged, become pharmaceutical composition.
Volatile oil part (composition combination one): prescription drug is through pulverizing the volatility oily material that the method for employing steam distillation extracts.Yield is the 0.5-3% of medical material weight.Wherein containing a plurality of components (by the content descending order) through the GC-MS analysis comprising:
Atractylone (Atractylon), atractylodes lactone A (Butenolide A), atractylodes lactone B (ButenolideB), ligustilide (ligustilide) and derivant thereof, 3-β-acetoxyl group atractylone (3-β-Acetoxyatractylon), celery alkane dienone (Selina-4 (14), 7 (11)-dien-8-one), group of Buddhists going together on a pilgrimage alkene, atractylol etc.The animal drug effect studies show that obviously to suppress the Small Intestine that causes because of neostigmine load mice hyperfunction, improving the Small Intestine that atropine causes is subjected to press down state: can significantly promote the normal mouse intestinal to advance, increase mice with spleen deficiency spleen index, thymus index, significantly reduce the mouse writhing number of times that causes by acetic acid.Experiment to the influence of the rat gastrointestinal tract dysfunction due to the reserpine: after the continuous modeling of rat reserpine, MTL level in body weight, food ration, thymus index, spleen index, blood plasma and the jejunum tissue homogenate and normal control group relatively significantly reduce (P<0.01).The component of different parts, compositions extract administration group and model group comparison can improve above-mentioned condition to some extent, wherein the MTL level in body weight, food ration, thymus index, blood plasma and the jejunum tissue homogenate.The experiment of mucosa injury situation: the administration group of the component of different parts, compositions extract is compared with model group, and all there were significant differences (P<0.05).
Dichloromethane extraction position component (composition combination two): prescription drug adopts dichloromethane to extract the compositions of the chemical constituent of gained behind the silica gel column chromatography from the insoluble part of petroleum ether.
Through HPLC, TLC, IR, NHR, MS, analyses such as UV wherein mainly contain studies on alkaloid constituents bag expansion more than 3 kinds: tetramethylpyazine--ligustrazine (ligustrazine, tetramethylpyrazine-TMP), isoleucyl-knot propylhomoserin lactams, perlolyrine (Perlolyrine).The animal drug effect studies show that obviously to suppress the Small Intestine that causes because of neostigmine load mice hyperfunction, improve the Small Intestine that atropine causes and be subjected to press down state: increase mice with spleen deficiency spleen index, thymus index, significantly reduce the mouse writhing number of times that causes by acetic acid.Experiment to the influence of the rat gastrointestinal tract dysfunction due to the reserpine: after the continuous modeling of rat reserpine, MTL level in body weight, food ration, thymus index, spleen index, blood plasma and the jejunum tissue homogenate and normal control group relatively significantly reduce (P<0.01).The component of different parts, compositions extract administration group and model group comparison can improve above-mentioned condition to some extent, wherein the MTL level in body weight, food ration, thymus index, blood plasma and the jejunum tissue homogenate.The experiment of mucosa injury situation: the administration group of the component of different parts, compositions extract is compared with model group, and all there were significant differences (P<0.05).
Ethyl acetate extraction position component: prescription drug adopts ethyl acetate to extract the compositions of the chemical constituent of gained behind the silica gel column chromatography from the insoluble part of dichloromethane.Totally two groups: EtOAC1 composition group and EtOAC2 composition group.
EtOAC1 (composition combination three): through HPLC, TLC, IR, NHR, MS, analyses such as UV wherein mainly contain 5 kinds of phenols chemical constituents.Ferulic acid (ferculic acid), cnidium lactone, chuanxingol (chuanxiongol), chrysophanol (chrysophanol), paeonol (paeonel).
The animal drug effect studies show that obviously to suppress the Small Intestine that causes because of neostigmine load mice hyperfunction, improving the Small Intestine that atropine causes is subjected to press down state: can significantly promote the normal mouse intestinal to advance, increase mice with spleen deficiency spleen index, thymus index, significantly reduce the mouse writhing number of times that causes by acetic acid.Experiment to the influence of the rat gastrointestinal tract dysfunction due to the reserpine: after the continuous modeling of rat reserpine, MTL level in body weight, food ration, thymus index, spleen index, blood plasma and the jejunum tissue homogenate and normal control group relatively significantly reduce (P<0.01).The component of different parts, compositions extract administration group and model group comparison can improve above-mentioned condition to some extent, wherein the MTL level in body weight, food ration, thymus index, blood plasma and the jejunum tissue homogenate.The experiment of mucosa injury situation: the administration group of the component of different parts, compositions extract is compared with model group, and all there were significant differences (P<0.05).
EtOAC2 (composition combination four).Through HPLC, TLC, IR, NHR, MS, analyses such as UV wherein mainly contain following chemical constituent.Saikogenin A-G (saikogenin A-G), enoxolone (glycyrrhetinic acid), Radix Glycyrrhizae aglycon (liquiritigenin), isoliquiritin unit (liquiritigenin), nimbecetin (Kaempferol), isoliquiritigenin (isoliquiritigenin), Quercetin (quercetin), isoquercitin (isoquercetin), isorhamnetin (isorhamnetin) etc.The animal drug effect studies show that obviously to suppress the Small Intestine that causes because of neostigmine load mice hyperfunction, improving the Small Intestine that atropine causes is subjected to press down state: can significantly promote the normal mouse intestinal to advance, increase mice with spleen deficiency spleen index, thymus index, significantly reduce the mouse writhing number of times that causes by acetic acid.Experiment to the influence of the rat gastrointestinal tract dysfunction due to the reserpine: after the continuous modeling of rat reserpine, MTL level in body weight, food ration, thymus index, spleen index, blood plasma and the jejunum tissue homogenate and normal control group relatively significantly reduce (P<0.01).The component of different parts, compositions extract administration group and model group comparison can improve above-mentioned condition to some extent, wherein the MTL level in body weight, food ration, thymus index, blood plasma and the jejunum tissue homogenate.The experiment of mucosa injury situation: the administration group of the component of different parts, compositions extract is compared with model group, and all there were significant differences (P<0.05).
The relevant component in n-butanol extraction position: prescription drug adopts the extraction of n-butyl alcohol from the insoluble part of ethyl acetate, the compositions of the chemical constituent of gained behind the silica gel column chromatography.Totally two groups: BuoH1 composition group and BuoH2 composition group.
BuoH1 (composition combination five): through HPLC, TLC, IR, NHR, MS, analyses such as UV wherein mainly contain flavone and glycoside thereof: puriri glycoside II, liquirtin (liquiritin), isoliquiritin (isoliquiritin), Neoliquiritin (neoliquiritin), isoliquiritigenin (isoliquiritigenin), globulariacitrin (Rutin), the glycoside of nimbecetin: Kaempferitrin (kaempferitrin), nimbecetin-7-rhamnoside (Kaempferol-7-rhamnoside), the Arabic glucoside of nimbecetin-3-0-α-L-furan-7-0-α-L-pyrans rhamnoside, narcissin (narcissin).The animal drug effect studies show that obviously to suppress the Small Intestine that causes because of neostigmine load mice hyperfunction, improving the Small Intestine that atropine causes is subjected to press down state: can significantly promote the normal mouse intestinal to advance, increase mice with spleen deficiency spleen index, thymus index, significantly reduce the mouse writhing number of times that causes by acetic acid.Experiment to the influence of the rat gastrointestinal tract dysfunction due to the reserpine: after the continuous modeling of rat reserpine, MTL level in body weight, food ration, thymus index, spleen index, blood plasma and the jejunum tissue homogenate and normal control group relatively significantly reduce (P<0.01).The component of different parts, compositions extract administration group and model group comparison can improve above-mentioned condition to some extent, wherein the MTL level in body weight, food ration, thymus index, blood plasma and the jejunum tissue homogenate.The experiment of mucosa injury situation: the administration group of the component of different parts, compositions extract is compared with model group, and all there were significant differences (P<0.05).
BuoH2 (composition combination six).Through HPLC, TLC, IR, NHR, MS, analyses such as UV wherein mainly contain Saponin or terpene glycoside chemical constituent: glycyrrhizic acid (glycyrrhizin), glycyrrhizin A-K (glycyrrhizin A-K), saikosaponin A-F (saikosaponin A-F), paeoniflorin (paeoniflorin), paeoniflorin (paeonin), peony lactone glycoside (albiforin), oxypaeoniflorin (oxypaeoniflorin), hydroxypaeoniflorin, benzoylpaeoniflorin (benzoylpaeoniflorin), paeonolide (paeonoside) Radix Pseudostellariae Saponin A (pseudostellarinoside A), point leaf gypsoside D (acutifoliside D).The animal drug effect studies show that obviously to suppress the Small Intestine that causes because of neostigmine load mice hyperfunction, improving the Small Intestine that atropine causes is subjected to press down state: can significantly promote the normal mouse intestinal to advance, increase mice with spleen deficiency spleen index, thymus index, significantly reduce the mouse writhing number of times that causes by acetic acid.Experiment to the influence of the rat gastrointestinal tract dysfunction due to the reserpine: after the continuous modeling of rat reserpine, MTL level in body weight, food ration, thymus index, spleen index, blood plasma and the jejunum tissue homogenate and normal control group relatively significantly reduce (P<0.01).The component of different parts, compositions extract administration group and model group comparison can improve above-mentioned condition to some extent, wherein the MTL level in body weight, food ration, thymus index, blood plasma and the jejunum tissue homogenate.The experiment of mucosa injury situation: the administration group of the component of different parts, compositions extract is compared with model group, and all there were significant differences (P<0.05).
Water-soluble component (composition combination seven): prescription drug adopts pure water to extract from the insoluble part of n-butyl alcohol, through ethanol precipitation, obtains total polysaccharides behind tannic acid or the ion exchange resin deproteinization, obtaining molecular weight through sephadex chromatography (Sephadex G-100) processing is 150000,120000,90000,46000,32000,15000 single component, hydrolysis is after paper chromatographic analysis detects galactose, glucose, rhamnose, arabinose, and galacturonic acid, glucuronic acid.Through HPLC, TLC, IR, NHR, MS, analyses such as UV wherein mainly contain pachymose (pachymic acid), pachyman (β-pachyman), the pachymaran (compositions of the polysaccharide macro-molecular composition of β-pachymaran), Angelica Polysaccharide (glycyrrizan UC).The animal drug effect studies show that obviously to suppress the Small Intestine that causes because of neostigmine load mice hyperfunction, improving the Small Intestine that atropine causes is subjected to press down state: can significantly promote the normal mouse intestinal to advance, increase mice with spleen deficiency spleen index, thymus index, significantly reduce the mouse writhing number of times that causes by acetic acid.Experiment to the influence of the rat gastrointestinal tract dysfunction due to the reserpine: after the continuous modeling of rat reserpine, MTL level in body weight, food ration, thymus index, spleen index, blood plasma and the jejunum tissue homogenate and normal control group relatively significantly reduce (P<0.01).The component of different parts, compositions extract administration group and model group comparison can improve above-mentioned condition to some extent, wherein the MTL level in body weight, food ration, thymus index, blood plasma and the jejunum tissue homogenate.The experiment of mucosa injury situation: the administration group of the component of different parts, compositions extract is compared with model group, and all there were significant differences (P<0.05).
Adopt following extraction scheme can obtain the various combination of above each component:
Extract E and component: the Chinese medicine compound compositions adopts water extraction, after suitably concentrating, adds Different concentrations of alcohol, and is centrifugal after leaving standstill, and gets supernatant concentration, obtains.Through HPLC, TLC, IR, NHR, MS, analyses such as UV wherein mainly contain composition combination two, three, four, five, six.The total solid yield is the 14-18% of medical material weight.
Extract S and component: the Chinese medicine compound compositions adopts water extraction, after suitably concentrating, through silicagel column repeatedly chromatography obtain the different composition of a plurality of polarity respectively and make up, through HPLC, TLC, IR, NHR, MS, analyses such as UV are respectively composition combination two, three, four, five, six, seven.
Extract L and component: the Chinese medicine compound compositions adopts water extraction, obtains a plurality of different compositions combinations through ion exchange column exchange absorption.Through HPLC, TLC, IR, NHR, MS, analyses such as UV wherein are respectively composition combination two, three, four, five.
Extract G and component: the Chinese medicine compound compositions adopts water extraction, after suitably concentrating, and after high speed centrifugation is handled, the component of water-soluble solution.Obtain a plurality of different compositions combinations.Through HPLC, TLC, IR, NHR, MS, analyses such as UV wherein are respectively composition combination two, three, four, five.The total solid yield is the 18-24% of medical material weight.
Extract D and component: the Chinese medicine compound compositions adopts water extraction, and eluting obtains a plurality of different compositions combinations behind absorption with macroporous adsorbent resin.Through HPLC, TLC, IR, NHR, MS, analyses such as UV wherein are respectively composition combination two, three, four, five, six, seven.The solid yield is the 2.0-7.0% of medical material weight.
Extract C and component: the Chinese medicine compound compositions adopts water extraction, after suitably concentrating, through high speed centrifugation, obtains different composition combinations after the hyperfiltration treatment, through HPLC, TLC, and IR, NHR, MS, analyses such as UV wherein are respectively combination two, three, four, five, six, seven.The total solid yield is the 10-15% of medical material weight.
Steam distillation thing and component: the volatility oily material that the Chinese medicine compound compositions adopts the method for steam distillation to extract, yield is the 1-3% of medical material weight.Wherein contain composition combination one through the GC-MS analysis.Store for future use through the beta-cyclodextrin inclusion compound solidification.
Need to prove: above-mentioned each component is the main component of described " extract ", and its actual constituent is not limited thereto, and should limit with its raw material and extracting method and be somebody's turn to do " extract ".
More than the 3rd, the 4th describedly " on above-mentioned basic side's basis, increase other composition; On the basis of the extract of above-mentioned Chinese medicine composition, increase other composition ", the component that can increase have in the following four class medicines any one or multiple.Plant-based medicine wherein can be that the corresponding plant of employing (plant species is as the criterion with the plant species of Chinese Pharmacopoeia regulation) is the various process of preparing Chinese medicine processed goods of feedstock production.
Increasable first kind medicine: the Rhizoma Atractylodis Macrocephalae, Rhizoma Chuanxiong, Poria, Fructus Aurantii Immaturus, Ramulus Cinnamomi, Pericarpium Citri Reticulatae, Radix Saposhnikoviae,, 1 flavor or 2 flavors or 3 flavors in the Radix Angelicae Sinensis, the Rhizoma Pinelliae, Rhizoma Coptidis, Radix Et Rhizoma Rhei, Radix Scutellariae, Cortex Albiziae, the consumption of each component is by the general consumption of pharmacopeia defined, or concrete prescription consumption below adopting.
Increase this quasi drugs and can constitute following each scheme:
Prescription 1~5 diarrhoea, constipation, stomachache, the alternating diarrhea and constipation that is mainly used in various degree.
1, Radix Bupleuri 9 grams, the Radix Paeoniae Alba 9 grams, Radix Pseudostellariae 6 grams, Radix Glycyrrhizae 6 grams.
2, Radix Bupleuri 12 grams, the Radix Paeoniae Alba 12 grams, Radix Pseudostellariae 6 grams, Radix Glycyrrhizae 6 grams.
3, Radix Bupleuri 15 grams, the Radix Paeoniae Alba 18 grams, Radix Pseudostellariae 9 grams, Radix Glycyrrhizae 9 grams.
4, Radix Bupleuri 12 grams, the Radix Paeoniae Alba 27 grams, Radix Pseudostellariae 6 grams, Radix Glycyrrhizae 9 grams.
5, Radix Bupleuri 9 grams, the Radix Paeoniae Alba 9 grams, Radix Pseudostellariae 6 grams, the Rhizoma Atractylodis Macrocephalae 9 grams, Radix Glycyrrhizae 6 grams.
Prescription 6~10 diarrhoea, constipation, stomachache, the alternating diarrhea and constipations that are mainly used in various degree, and with diarrhoea, the pain symptom of heavier degree.
6, Radix Bupleuri 9 grams, the Radix Paeoniae Alba 9 grams, Rhizoma Chuanxiong 6 grams, Radix Pseudostellariae 6 grams, Radix Glycyrrhizae 6 grams.
7, Radix Bupleuri 9 grams, the Radix Paeoniae Alba 18 grams, Radix Pseudostellariae 6 grams, Radix Glycyrrhizae 9 grams, Pericarpium Citri Reticulatae 9 grams.
8, Radix Bupleuri 9 grams, the Radix Paeoniae Alba 9 grams, Radix Pseudostellariae 6 grams, Radix Glycyrrhizae 6 grams, Fructus Aurantii Immaturus 9 grams.
9, Radix Bupleuri 9 grams, the Radix Paeoniae Alba 9 grams, Radix Pseudostellariae 6 grams, Radix Glycyrrhizae 6 grams, Radix Scutellariae 9 grams.
10, Radix Bupleuri 9 grams, the Radix Paeoniae Alba 12 grams, Radix Pseudostellariae 6 grams, Radix Glycyrrhizae 6 grams, Pericarpium Citri Reticulatae 6-9 gram, Radix Saposhnikoviae 6-9 gram.
Prescription 11~17 is mainly used in diarrhoea, constipation or alternating diarrhea and constipation, and symptom such as, agitation poor with sleeping in various degree.
11, Radix Bupleuri 9 grams, the Radix Paeoniae Alba 9 grams, Radix Pseudostellariae 6 grams, Radix Glycyrrhizae 6 grams, the Rhizoma Atractylodis Macrocephalae 9 grams, Radix Saposhnikoviae 6-9 gram.
12, Radix Bupleuri 9 grams, the Radix Paeoniae Alba 9 grams, Radix Pseudostellariae 6 grams, Radix Glycyrrhizae 6 grams, the Rhizoma Atractylodis Macrocephalae 9 grams, Rhizoma Coptidis 6-9 gram.
13, Radix Bupleuri 9 grams, the Radix Paeoniae Alba 9 grams, Radix Pseudostellariae 6 grams, Radix Glycyrrhizae 6 grams, the Rhizoma Atractylodis Macrocephalae 9 grams, Poria 9 grams.
14, Radix Bupleuri 9 grams, the Radix Paeoniae Alba 9 grams, Radix Pseudostellariae 6 grams, Radix Glycyrrhizae 6 grams, Cortex Albiziae 9 grams.
15, Radix Bupleuri 9 grams, the Radix Paeoniae Alba 9 grams, Radix Pseudostellariae 6 grams, Radix Glycyrrhizae 6 grams, Fructus Aurantii Immaturus 6 grams.
16, Radix Bupleuri 9 grams, the Radix Paeoniae Alba 9 grams, Radix Pseudostellariae 6 grams, Radix Glycyrrhizae 6 grams, Poria 9, the Rhizoma Atractylodis Macrocephalae 9 grams.
17, Radix Bupleuri 9 grams, the Radix Paeoniae Alba 9 grams, Radix Pseudostellariae 6 grams, Radix Glycyrrhizae 6 grams, Rhizoma Chuanxiong 6 grams.
18, Radix Bupleuri 9 grams, the Radix Paeoniae Alba 9 grams, Radix Pseudostellariae 6 grams, Radix Glycyrrhizae 6 grams, Radix Et Rhizoma Rhei 6 grams, the Rhizoma Pinelliae 3 grams.
Prescription 19~24 is mainly used in diarrhoea, constipation or alternating diarrhea and constipation, and with abdomen in various degree rise, symptoms such as anorexia, agitation
19, Radix Bupleuri 9 grams, the Radix Paeoniae Alba 9 grams, Radix Pseudostellariae 6 grams, the Rhizoma Atractylodis Macrocephalae 9 grams, Radix Glycyrrhizae 6 grams, Fructus Aurantii Immaturus 6 grams.
20, Radix Bupleuri 9 grams, the Radix Paeoniae Alba 9 grams, Radix Pseudostellariae 6 grams, Radix Glycyrrhizae 6 grams, the Rhizoma Atractylodis Macrocephalae 9 grams, Rhizoma Coptidis 6-9 gram.
21, Radix Bupleuri 9 grams, the Radix Paeoniae Alba 9 grams, Radix Pseudostellariae 6 grams, Radix Glycyrrhizae 6 grams, Pericarpium Citri Reticulatae 6 grams, Fructus Aurantii Immaturus 6 grams.
22, Radix Bupleuri 9 grams, the Radix Paeoniae Alba 9 grams, Radix Pseudostellariae 6 grams, the Rhizoma Atractylodis Macrocephalae 9 grams, Radix Glycyrrhizae 6 grams, Radix Scutellariae 9 grams, Pericarpium Citri Reticulatae 9 grams.
23, Radix Bupleuri 9 grams, the Radix Paeoniae Alba 9 grams, Radix Pseudostellariae 6 grams, the Rhizoma Atractylodis Macrocephalae 9 grams, Radix Glycyrrhizae 6 grams, Radix Saposhnikoviae 9 grams.
24, Radix Bupleuri 9 grams, the Radix Paeoniae Alba 9 grams, Radix Pseudostellariae 6 grams, the Rhizoma Atractylodis Macrocephalae 9 grams, Radix Glycyrrhizae 6 grams, Rhizoma Chuanxiong 6 grams, Poria 9 grams.
Prescription 25~28 is mainly used in diarrhoea, constipation or alternating diarrhea and constipation, and with diseases such as becoming thin in various degree, fear of cold.
25, Radix Bupleuri 9 grams, the Radix Paeoniae Alba 9 grams, Radix Pseudostellariae 6 grams, the Rhizoma Atractylodis Macrocephalae 9 grams, Radix Glycyrrhizae 6 grams, Rhizoma Chuanxiong 6 grams.
26, Radix Bupleuri 9 grams, the Radix Paeoniae Alba 9 grams, Radix Pseudostellariae 6 grams, the Rhizoma Atractylodis Macrocephalae 9 grams, Radix Glycyrrhizae 6 grams, Radix Angelicae Sinensis 6 grams, Rhizoma Coptidis 3 grams.
27, the Rhizoma Atractylodis Macrocephalae 9 grams, Poria 9 grams, Radix Glycyrrhizae 6 grams, Radix Bupleuri 6 grams, Radix Pseudostellariae 6 grams, the Radix Paeoniae Alba 12 grams, the Radix Astragali 9 grams.
28, Radix Bupleuri 9 grams, the Radix Paeoniae Alba 9 grams, Radix Pseudostellariae 6 grams, the Rhizoma Atractylodis Macrocephalae 9 grams, Radix Glycyrrhizae 6 grams, Ramulus Cinnamomi 6 grams.
The increasable second class medicine: the extract (assembly of the extract of the water of various pharmaceutical compositions, ethanol or organic solvent, a kind of and multiple extract or chemical constituent that can be certain or some drugs in the above first kind medicine.Extract combination body after the extract that comprises the combination of a kind of and multiple different pharmaceutical makes up once more.)
The extract of described certain or some drugs (also can be described as: " the chemical constituent combination of medicine opposed polarity and the chemical constituent combination of adopting different separation methods to obtain ") is meant: the water-soluble component in the insoluble position of n-butanol extraction component, n-butyl alcohol in the insoluble part of ethyl acetate extraction component, ethyl acetate in the insoluble part of dichloromethane extraction component, dichloromethane in volatile oil part, the aqueous extract position.See sketch map (Fig. 1).Purifies and separates drying: aqueous extract, vacuum concentration, ethanol precipitation, resin absorption, resins exchange, the component that technical method alone or in combination such as high speed centrifugation, cyclodextrin inclusion compound etc. obtains.See sketch map (Fig. 2).
Increasable the 3rd class medicine: the chemical compound that can be natural origin or synthetic.
For example, compositions adds one of following medicine: dioctahedral smectite (SEMECDA) 2-10g, domperidone (domperidone) 5-20mg, cisapride (cisapride) 1-20mg, for adding thiophene sieve (Tegaserod) 2-15mg, alosetron (Alosetron) 0.5-3mg, otilonium Bromide (Spasmomen) 50-200mg, pinaverium bromide (Pinaverum bromide) 50-200mg, Trimebutine Maleate (Trimebutine) 0.2-1.5g, butyric acid bacteria 40-200mg etc.
The preparation method of the above treatment bowel dysfunction Chinese medicine composition (and modern formulation), step is as follows:
1, above-mentioned composition is adopted water, ethanol or other organic solvent extraction;
2, the compositions behind above-mentioned water, ethanol or other organic solvent extraction is adopted one or more purifies and separates of following method: vacuum concentration, ethanol precipitation, resin absorption, resins exchange, high speed centrifugation, technical methods such as cyclodextrin inclusion compound obtain extract after handling;
3, above extract merges, direct or the purified again back of separating adds suitable pharmaceutic adjuvant, is prepared into granule, capsule, tablet, oral liquid, parenteralia (subcutaneous, blood vessel, muscle administration) respectively, through the suppository of skin or mucosal preparation, rectally; Perhaps set by step 4:
4, above medicine adds granule, capsule, tablet, percutaneous or the mucosal preparation of suitable pharmaceutic adjuvant preparation, the suppository of rectally after crushed.
The indication scope of above Chinese medicine composition:
People or other mammiferous gastrointestinal function disorder.Comprise:
1, the irritable bowel syndrome that brings out by Nervous and Mental Factors (bowel dysfunction).
2, by food or inflammation bring out irritable bowel syndrome (bowel dysfunction)
3, the clinical main performance diarrhoea of IBS, constipation, stomachache, alternating diarrhea and constipation; Companion anorexia, asthenia, poor, the agitation of becoming thin, sleep etc.Modern medicine is divided into diarrhea-type, constipation type.Clinical symptoms is with irregular stomachache, abdominal distention, diarrhoea, and the stool character changes and defecation frequency increases and is main performance.Get rid of other intestinal organic diseases: get rid of thyroid disease, diabetes, nephropathy, cardiovascular diseases, disease of hematopoietic system, ulcerative colitis, clone disease, chronic dysentery, peptic ulcer, chronic hepatitis, anus etc., prevent false positive.Stomachache before generally having following feature (1) is just alleviated after an action of the bowels; Enterokinesia obviously increases when (2) suffering from abdominal pain; (3) constipation or diarrhoea; (4) overall health of patients is general good or show with the general neurosis.(5) the spontaneous wriggling of colon is unusual, and intestinal sensitivity increases.(6) internal organs hyperpathia etc.
4, relevant disease comprises: functional bowel disorder (functional diarrhea, functional constipation), acute and chronic functional abdominal pain or abdominal distention or with the stomach symptom, periodically stomachache or abdominal distention, functional dyspepsia, stomachache stomach discomfort etc.
The result of study of the animal pharmacodynamics of the present composition (comprise the above, by extract or contain the various combination of chemicals):
Pharmacodynamic experiment is the result show:
1. to the component of the experiment different parts of mice with spleen deficiency influence, body weight, the food ration that the compositions extract can significantly increase mice with spleen deficiency to some extent, improve sign, loose stool level, increase mice with spleen deficiency spleen index, the thymus index of mice with spleen deficiency, regulate the gastrointestinal function of mice with spleen deficiency, relatively there were significant differences (P<0.05) with model group.
2. to the experiment of the intestinal propulsion influence of mice neostigmine load/atropine load: it is hyperfunction that the component of different parts, compositions extract can obviously suppress the Small Intestine that causes because of neostigmine load mice to some extent, improve the Small Intestine that atropine causes and be subjected to press down state, relatively there were significant differences (P<0.05) with model group, points out it that intestinal function is had dual regulation.
3. the experiment of the influence of the mouse writhing pain due to the Dichlorodiphenyl Acetate: the component of different parts, compositions extract can significantly reduce the mouse writhing number of times that is caused by acetic acid to some extent.
4. the experiment of the influence of the rat gastrointestinal tract dysfunction due to the reserpine: after the continuous modeling of rat reserpine, MTL level in body weight, food ration, thymus index, spleen index, blood plasma and the jejunum tissue homogenate and normal control group relatively significantly reduce (P<0.01).The component of different parts, compositions extract administration group and model group comparison can improve above-mentioned condition to some extent, wherein the MTL level in body weight, food ration, thymus index, blood plasma and the jejunum tissue homogenate.
5. membrane damage situation experiment: the administration group of the component of different parts, compositions extract is compared with model group, and all there were significant differences (P<0.05).
Experimental technique and result
One, the compositions extract is to the influence of mice with spleen deficiency:
Get 60 of Male Kunming strain mice, be divided into 6 groups at random.Except that the normal control group, all the other each groups all give Radix Et Rhizoma Rhei decocting liquid, duplicate the Mice with Spleen model.Continuous gastric infusion 6d.0.1g·kg
-1·d
-1。The component of different parts, compositions extract and model group are relatively organized a t check.Compare with positive drug group and model group, can significantly increase body weight, the food ration of mice with spleen deficiency to some extent, improve sign, loose stool level, increase mice with spleen deficiency spleen index, the thymus index of mice with spleen deficiency, regulate the gastrointestinal function of mice with spleen deficiency.The results are shown in Table 2.
Table 2 compositions extract is to the influence of mice with spleen deficiency (X ± S)
Administration precursor intestinal propulsion
After one week of administration
The heavy thymus index spleen index of group
Body weight (g) percentage rate (%)
(g)
Normal control group 19.03 ± 1.23 26.34 ± 1.46 0.0025 ± 0.0010 0.0059 ± 0.0019 57.6 ± 5.36
Model group 19.29 ± 1.42 22.93 ± 2.09
△ △0.0013 ± 0.0007
△ △0.0039 ± 0.0013
△ △69.54 ± 6.23
△
Positive group 18.95 ± 1.21 25.42 ± 2.31
*0.0019 ± 0.0003
*0.0052 ± 0.0011
*63.1 ± 5.49
*
CH
2Cl
2Composition group 19.17 ± 1.08 24.44 ± 2.33
*0.0018 ± 0.0004
*0.0043 ± 0.0014
*68.38 ± 6.43
EtOAC1 composition group 19.43 ± 1.52 25.72 ± 3.72
*0.0020 ± 0.0006
*0.0053 ± 0.0009
*60.2 ± 6.31
*
EtOAC2 composition group 19.32 ± 1.19 26.05 ± 2.38
*0.0024 ± 0.0006
*0.0056 ± 0.0012
*58.1 ± 4.75
*
BuoH1 composition group 19.05 ± 1.63 24.12 ± 1.31
*0.0026 ± 0.0008
*0.0053 ± 0.0012
*65.2 ± 4.98
BuoH2 composition group 19.26 ± 1.42 23.97 ± 2.73
*0.0022 ± 0.0005
*0.0056 ± 0.0009
*58.9 ± 2.33
Water-soluble component 18.33 ± 1.21 26.52 ± 1.04
*0.0023 ± 0.0009
*0.0060 ± 0.0013
*58.1 ± 4.62
*
Volatile oil part 19.93 ± 1.08 26.42 ± 1.36
*0.0016 ± 0.0004
*0.0047 ± 0.0011
*60.1 ± 3.11
*
Extract D and component 19.83 ± 1.52 25.91 ± 1.71
*0.0020 ± 0.0006
*0.0040 ± 0.0009
*60.2 ± 6.41
*
Extract G and component 19.22 ± 1.19 26.03 ± 2.81
*0.0024 ± 0.0006
*0.0057 ± 0.0006
*59.5 ± 4.90
*
Extract C and component 19.37 ± 1.05 25.31 ± 2.71
*0.0019 ± 0.0002
*0.0055 ± 0.0015
*61.2 ± 2.83
*
Extract S and component 19.93 ± 1.26 26.49 ± 1.83
*0.0021 ± 0.0003
*0.0055 ± 0.0008
*60.5 ± 5.12
*
Extract E and component 19.97 ± 1.72 26.27 ± 2.25
*0.0024 ± 0.0006
*0.0062 ± 0.0011
*59.9 ± 1.77
*
Extract L and component 19.52 ± 1.13 24.25 ± 2.38
*0.0020 ± 0.0002
*0.0042 ± 0.0005
*60.5 ± 5.23
*
Steam distillation thing and 19.70 ± 1.94 65.2 ± 2.42
*
25.85±2.32
* 0.0024±0.0007
* 0.0050±0.0015
*
Component
Compare with matched group:
△P<0.05,
△ △P<0.01.Compare with model group:
*P<0.05,
*P<0.01.
Two, the compositions extract is to the influence of the intestinal propulsion of mice neostigmine load/atropine load:
Get 60 of Kunming mouses, be divided into 6 groups at random by body weight.Gastric infusion, 5d continuously.Except that the normal control group, all the other respectively organize the equal subcutaneous injection neostigmine of mice 1mgkg
-1All mices are all irritated the carbon powder 0.1ml10g of stomach 5%
-1, putting to death cuts open the belly takes out the gastrointestinal section, and the percentage ratio that it accounts for the small intestinal total length is calculated to the distance of pylorus in record carbon ink forward position.The component at variant position, compositions extract and model group are relatively organized a t check.The intestinal propulsion experimental technique of atropine load removes model group and administration group subcutaneous injection atropine 5mgkg with the experiment of neostigmine load intestinal propulsion in addition
-1Load.The results are shown in Table 3.
Administration group and positive drug group and model group relatively, it is hyperfunction obviously to suppress the Small Intestine that causes because of neostigmine load mice to some extent, improves the Small Intestine that atropine causes and is subjected to press down state, points out it that intestinal function is had dual regulation.
Table 3 compositions extract is to the influence of the intestinal propulsion of mice neostigmine load/atropine load (X ± S)
Group neostigmine load atropine load
Normal control group 59.58 ± 4.46 59.58 ± 4.46
Model group 79.33 ± 9.48
△ △33.03 ± 10.13
△ △
Positive group 70.34 ± 6.46
*43.56 ± 10.63
*
CH
2Cl
2Composition group 74.53 ± 7.78
*38.87 ± 10.06
*
EtOAC1 composition group 66.14 ± 4.70
*39.10 ± 10.65
*
EtOAC2 composition group 68.08 ± 8.00
*42.68 ± 9.01
*
BuoH1 composition group 67.94 ± 6.51
*34.82 ± 10.46
*
BuoH2 composition group 63.93 ± 8.75
*49.10 ± 5.38
*
Water-soluble component 66.51 ± 6.57
*51.41 ± 9.83
*
Volatile oil part 63.04 ± 8.02
*52.32 ± 12.47
*
Extract D and component 68.16 ± 3.55
*47.51 ± 8.51
*
Extract G and component 70.53 ± 7.78
*42.72 ± 11.37
*
Extract C and component 62.57 ± 5.38
*44.57 ± 7.47
*
Extract S and component 64.71 ± 6.30
*48.16 ± 13.88
*
Extract E and component 70.14 ± 5.33
*45.81 ± 10.62
*
Extract L and component 71.13 ± 2.00
*37.62 ± 8.25
*
Steam distillation thing and component 72.51 ± 6.29
*40.13 ± 15.95
*
Compare with matched group:
△P<0.05,
△ △P<0.01.Compare with model group:
*P<0.05,
*P<0.01.
Three, the influence of the mouse writhing pain due to the compositions extract Dichlorodiphenyl Acetate:
Get Kunming mouse, by the body weight grouping.The administration group is given and the different components extract respectively.After the last administration, the equal lumbar injection 0.6% acetum 0.2ml/ of each Mus, the writhing response number of times of appearance in the observation injection back 15min (abdominal part indent, stretching, extension hind leg, buttocks are raised), and calculate the analgesia percentage rate.The results are shown in Table 4.The component of different parts, compositions extract and positive drug group and model group relatively can significantly reduce the mouse writhing number of times that is caused by acetic acid to some extent.
The influence of the mouse writhing pain due to the table 4 compositions extract Dichlorodiphenyl Acetate (X ± S)
Group is turned round body number of times analgesia percentage rate %
Model group 23.4 ± 13.7
Positive group 5.2 ± 4.8
*77.5
CH
2Cl
2Composition group 12.7 ± 10.3
*48.5
EtOAC1 composition group 8.0 ± 8.3
*66.5
EtOAC2 composition group 13.2 ± 7.7
*47.2
BuoH1 composition group 19.6 ± 16.8
*11.2
BuoH2 composition group 7.0 ± 4.2
*69.8
Water-soluble component 3.2 ± 6.3
*85.6
Volatile oil part 8.7 ± 8.2
*64.8
Extract D and component 11.0 ± 5.8
*51.6
Extract G and component 5.6 ± 7.3
*75.8
Extract C and component 7.2 ± 13.3
*68.1
Extract S and component 6.8 ± 3.9
*70.3
Extract E and component 6.7 ± 13.6
*70.6
Extract L and component 16.2 ± 9.6
*31.8
Steam distillation thing and component 17.1 ± 7.3
*33.0
Compare with model group:
*P<0.05
Four, the compositions extract is to the influence of the rat gastrointestinal tract dysfunction due to the reserpine:
Get the healthy adult male SD rat, be divided into 6 groups.Normal control group intraperitoneal injection of saline 5mlkg
-1D
-1, all the other respectively organize lumbar injection reserpine 0.5mgkg
-1D
-1, the component of different parts, compositions extract are given and the different components extract respectively simultaneously, and normal control group and model group are irritated stomach equal-volume distilled water, 1 d
-1.In the administration process, the feces and the sign of observing rat at any time change, and body weight, the food ration of weighing every day rat.Collect following specimen by MTL radioimmunity test kit behind the 14d continuously: blood plasma, jejunum tissue.Immediately take out each rat chest gland, spleen, weigh.Component, compositions extract and the model group at variant position are compared, organize a t check, the results are shown in Table 5, the continuous modeling of rat reserpine is after 14 days, MTL level in body weight, food ration, thymus index, spleen index, blood plasma and the jejunum tissue homogenate and normal control group relatively significantly reduce.MTL level in the body weight of the component of different parts, compositions extract, food ration, thymus index, blood plasma and the jejunum tissue homogenate is compared with model group, and notable difference is all arranged.
Table 5 compositions extract is to the influence of the rat gastrointestinal tract dysfunction due to the reserpine (X ± S)
Group body weight thymus index spleen index motilin in plasma jejunum homogenate MTL
369.5 0.0010 0.0036 131.01 1866.41
The normal control group
±17.85 ±0.0004 ±0.0011 ±98.65 ±663.22
264.9 0.0006 0.0027 40.52 498.86
Model group
±49.02
△△ ±0.0002
△ ±0.0005
△ ±24.62
△△ ±306.53
△△
315.8 0.0009 0.0035 121.75 1498.14
Positive group
±47.93* ±0.0002* ±0.0007* ±66.85* ±773.67**
287.9 0.0007 0.0031 111.14 1470.55
CH
2Cl
2The composition group
±41.48 ±0.0002
*?±0.0007
* ±49.18
* ±753.22
*
294.5 0.0009 0.0032 82.30 1841.44
EtOAC1 composition group
±53.2 ±0.0003
* ±0.0006
*?±54.07
* ±491.62*
321.5 0.0011 0.0034 102.41 1581.69
EtOAC2 composition group
±35.86* ±0.0002* ±0.0005* ±44.92* ±802.72**
344.5 0.0009 0.0033 125.06 1309.13
BuoH1 composition group
±15.35
* ±0.0002
* ±0.0008
* ±61.38
* ±592.41
*
326.9 0.0009 0.0029 119.51 1947.52
BuoH2 composition group
±61.50
△△ ±0.0003
* ±0.0013
* ±76.53
* ±397.40*
Water-soluble component 371.3 0.0015 0.0030 112.41 1647.94
±42.37* ±0.0002* ±0.0008* ±59.38* ±722.59**
286.5 0.0007 0.0029 94.71 961.17
Volatile oil part
±57.37 ±0.0002
*?±0.0014
* ±55.28
* ±732.72
*
372.5 0.0009 0.0038 83.05 1215.03
Extract D and component
±63.9 ±0.0003 ±0.0009
*?±47.13
* ±501.72*
378.3 0.0013 0.0025 114.06 1805.35
Extract G and component
±52.15* ±0.0003* ±0.0005* ±49.22* ±371.28**
352.5 0.0013 0.0035 128.49 1381.71
Extract C and component
±28.14 ±0.0004
*?±0.0012
* ±48.62
* ±530.16
*
346.7 0.0009 0.0036 102.52 1530.38
Extract S and component
±32.41
△△?±0.0003
* ±0.0009
* ±38.41
* ±582.47*
355.7 0.0009 0.0033 118.28 1791.49
Extract E and component
±50.69* ±0.0002* ±0.0005* ±61.02* ±379.51**
315.9 0.0007 0.0033 91.14 1074.39
Extract L and component
±37.51 ±0.0005
*?±0.0007
* ±18.39
* ±527.81
*
292.2 0.0009 0.0030 102.17 1273.14
Steam distillation thing and component
±61.3 ±0.0001
*?±0.0017
* ±48.61
* ±631.29*
Compare with matched group:
△P<0.05,
△ △P<0.01.Compare with model group: * P<0.05, * * P<0.01.
Five, the compositions extract is to the influence of the damage of gastrointestinal mucosa:
Get gastrointestinal tissue, naked eyes, light microscopic, transmission electron microscope observing mucosa injury situation the results are shown in Table 6.
The damage of table 6 gastrointestinal mucosa is observed
Group light microscopic Electronic Speculum
Normal control group normal mucosa epithelial cell marshalling, nothing comes off
Model group surface fracture mucomembranous epithelial cell is arranged loose, comes off in a large number
Positive group normal mucosa epithelial cell is arranged more neat, comes off on a small quantity
CH
2Cl
2Composition group normal mucosa epithelial cell is arranged loose, comes off on a small quantity
EtOAC1 composition group normal mucosa epithelial cell is near matched group, and nothing comes off
EtOAC2 composition group normal mucosa epithelial cell is near matched group, and nothing comes off
BuoH1 composition group normal mucosa epithelial cell is near matched group, and nothing comes off
BuoH2 composition group normal mucosa epithelial cell is near matched group, and nothing comes off
Water-soluble component normal mucosa epithelial cell is near matched group, and nothing comes off
Volatile oil part normal mucosa epithelial cell is near matched group, and nothing comes off
Extract D and component normal mucosa epithelial cell are near matched group, and nothing comes off
Extract G and component normal mucosa epithelial cell are near matched group, and nothing comes off
Extract C and component normal mucosa epithelial cell are near matched group, and nothing comes off
Extract S and component normal mucosa epithelial cell are near matched group, and nothing comes off
Extract E and component normal mucosa epithelial cell are near matched group, and nothing comes off
Extract L and component normal mucosa epithelial cell are near matched group, and nothing comes off
Steam distillation thing and component normal mucosa epithelial cell are near matched group, and nothing comes off
Clinical use is observed:
The compound that the invention provides Chinese medicine (comprises the above, by extract or contain the various combination of chemicals) on the basis of theory of Chinese medical science and pharmacological evaluation, through clinical observation, be used for the treatment of IBS and other gastrointestinal function disorders, effect is better.The result is as follows:
The selection of control drug:
In recent years there is the many cases clinical report to adopt dioctahedral smectite treatment IBS to obtain better effects, dioctahedral smectite all has the improvement effect to the multiple symptom of IBS, particularly aspect times of defecation and stool character, can be alleviated rapidly and improve at symptom after taking medicine, stool can recover normal after most patients 3-4 days.
The case choice criteria:
Select the 50 routine irritable bowel syndrome courses of disease the patient more than 1 month, case is selected: select to determine by Rome standard I I.All cases are through routine blood test, just routine, liver function, blood glucose, liver and gall pancreas B ultrasonic, fibro-colonoscope or intestinal barium agent radiography are got rid of organic disease.Clinical manifestation can be alleviated with stomachache behind abdominal distention, borborygmus, stomachache, the defecation based on diarrhoea.
Therapeutic process:
Male's 39 examples in the case, women's 31 examples; Be divided into treatment and organize 50 examples, matched group 20 examples.Two groups close in sex, age, clinical manifestation, and comparability is arranged.Treatment group: with the present invention's potion every day of writing out a prescription.2 week back doing well,improving person every days of treatment 2 times, 2 weeks of reuse.With the foundation of 4 weeks back clinical manifestation as the curative effect judgement.Matched group: dioctahedral smectite 3 restrains once, and every day 3 times, the course of treatment is the same.Be nonrandom grouping, treat have a blood test after 4 weeks routine, liver function, further consultation 1 time weekly in the therapeutic process understands that symptom changes, defecation character and number of times, looks into just conventional.
Efficacy evaluation
Produce effects: diarrhoea stops, and simultaneous phenomenon is obviously alleviated.Effectively: diarrhoea is obviously alleviated, and every day, defecation was 2 times, and simultaneous phenomenon takes a turn for the better.Invalid: as not reach above-mentioned standard.
The result observes
Prescription group of the present invention: 50 examples, produce effects 29 examples (58%), effective 12 examples (24%), invalid 9 examples (18%), total effective rate 82%.Matched group 20 examples, produce effects 4 examples (20%), effective 7 examples (35%), invalid 9 examples (45%), total effective rate 55%.The present invention's curative effect of writing out a prescription is higher than dioctahedral smectite, and treatment the fastest onset in plan side's is 5 days certainly.3 all stable curative effect show, stomachache and malaise symptoms significantly reduce, and function of intestinal canal improves (comprise that times of defecation and sense of urgency reduce, the stool character is improved), and the while was maintained during whole medication in doing well,improving appeared at around medication preceding.Invalid case extends the period of treatment and also can not improve curative effect, and two groups of medications there is no obvious adverse reaction, treatment back routine blood test, the equal no change of liver function.
Description of drawings
Fig. 1 separates sketch map for the different chemical position;
Fig. 2 is a process chart of the present invention.
The specific embodiment
Embodiment 1, writes out a prescription to be: Radix Bupleuri 6 grams, the Radix Paeoniae Alba 6 grams, Radix Pseudostellariae 3 grams, Radix Glycyrrhizae 6 grams.
Above-mentioned composition is adopted water, ethanol or other organic solvent extraction;
The purifies and separates drying: water or alcoholic acid extracting solution be through vacuum concentration, ethanol precipitation, resin absorption, resins exchange, high speed centrifugation, the extract that methods such as cyclodextrin inclusion compound obtain;
Above medicine adds granule, capsule, tablet, percutaneous or the mucosal preparation of suitable pharmaceutic adjuvant preparation, the suppository of rectally after crushed.
Embodiment 2, and is substantially the same manner as Example 1, but prescription is: Radix Bupleuri 18 grams, the Radix Paeoniae Alba 30 grams, Radix Pseudostellariae 18 grams, Radix Glycyrrhizae 15 grams.Preparation method changes into simultaneously:
Above-mentioned composition is adopted water, ethanol or other organic solvent extraction;
The purifies and separates drying: water or alcoholic acid extracting solution be through vacuum concentration, ethanol precipitation, resin absorption, resins exchange, high speed centrifugation, the extract that methods such as cyclodextrin inclusion compound obtain;
Direct or the purified back of separating of above extract adds suitable pharmaceutic adjuvant, is prepared into the suppository of granule, capsule, tablet, oral liquid, parenteralia, percutaneous or mucosal preparation, rectally respectively.
Embodiment 3, and is basic identical with embodiment 1 or 2, but prescription is: Radix Bupleuri 12 grams, the Radix Paeoniae Alba 12 grams, Radix Pseudostellariae 6 grams, Radix Glycyrrhizae 6 grams.
Embodiment 4, and is basic identical with embodiment 1 or 2, but prescription is: Radix Bupleuri 18 grams, the Radix Paeoniae Alba 30 grams, Radix Pseudostellariae 12 grams, Radix Glycyrrhizae 12 grams.
Embodiment 5, and is basic identical with embodiment 1 or 2, but prescription is: Radix Bupleuri 9 grams, the Radix Paeoniae Alba 9 grams, Radix Pseudostellariae 6 grams, Radix Glycyrrhizae 6 grams.
Embodiment 6, and is basic identical with embodiment 1 or 2, but prescription is: Radix Bupleuri 12 grams, the Radix Paeoniae Alba 12 grams, Radix Pseudostellariae 12 grams, Radix Glycyrrhizae 12 grams.
Embodiment 7, and is basic identical with embodiment 1 or 2, but prescription is: Radix Bupleuri 9 grams, the Radix Paeoniae Alba 9 grams, Radix Pseudostellariae 6 grams, Radix Glycyrrhizae 6 grams.
Embodiment 8, and is basic identical with embodiment 1 or 2, but prescription is: Radix Bupleuri 12 grams, the Radix Paeoniae Alba 12 grams, Radix Pseudostellariae 6 grams, Radix Glycyrrhizae 6 grams.
Embodiment 9, and is basic identical with embodiment 1 or 2, but prescription is: Radix Bupleuri 15 grams, the Radix Paeoniae Alba 18 grams, Radix Pseudostellariae 9 grams, Radix Glycyrrhizae 9 grams.
Embodiment 10, and is basic identical with embodiment 1 or 2, but prescription is: Radix Bupleuri 12 grams, the Radix Paeoniae Alba 27 grams, Radix Pseudostellariae 6 grams, Radix Glycyrrhizae 9 grams.
_ embodiment 11, and is basic identical with embodiment 1 or 2, but prescription is: Radix Bupleuri 12 grams, the Radix Paeoniae Alba 12 grams, Radix Pseudostellariae 6 grams, the Rhizoma Atractylodis Macrocephalae 9 grams, Radix Glycyrrhizae 6 grams.
Embodiment 12, and is basic identical with embodiment 1 or 2, but prescription is: Radix Bupleuri 9 grams, the Radix Paeoniae Alba 9 grams, Rhizoma Chuanxiong 6 grams, Radix Pseudostellariae 6 grams, Radix Glycyrrhizae 6 grams.
Embodiment 13, and is basic identical with embodiment 1 or 2, but prescription is: Radix Bupleuri 9 grams, the Radix Paeoniae Alba 18 grams, Radix Pseudostellariae 6 grams, Radix Glycyrrhizae 9 grams, Pericarpium Citri Reticulatae 9 grams.
Embodiment 14, and is basic identical with embodiment 1 or 2, but prescription is: Radix Bupleuri 9 grams, the Radix Paeoniae Alba 9 grams, Radix Pseudostellariae 6 grams, Radix Glycyrrhizae 6 grams, Fructus Aurantii Immaturus 9 grams.
Embodiment 15, and is basic identical with embodiment 1 or 2, but prescription is: Radix Bupleuri 9 grams, the Radix Paeoniae Alba 9 grams, Radix Pseudostellariae 6 grams, Radix Glycyrrhizae 6 grams, Radix Scutellariae 9 grams.
Embodiment 16, and is basic identical with embodiment 1 or 2, but prescription is: Radix Bupleuri 9 grams, the Radix Paeoniae Alba 12 grams, Radix Pseudostellariae 6 grams, Radix Glycyrrhizae 6 grams, Pericarpium Citri Reticulatae 6-9 gram, Radix Saposhnikoviae 6-9 gram.
Embodiment 17, and is basic identical with embodiment 1 or 2, but prescription is: Radix Bupleuri 9 grams, the Radix Paeoniae Alba 9 grams, Radix Pseudostellariae 6 grams, Radix Glycyrrhizae 6 grams, the Rhizoma Atractylodis Macrocephalae 9 grams, Radix Saposhnikoviae 6-9 gram.
Embodiment 18, and is basic identical with embodiment 1 or 2, but prescription is: Radix Bupleuri 9 grams, the Radix Paeoniae Alba 9 grams, Radix Pseudostellariae 6 grams, Radix Glycyrrhizae 6 grams, the Rhizoma Atractylodis Macrocephalae 9 grams, Rhizoma Coptidis 6-9 gram.
Embodiment 19, and is basic identical with embodiment 1 or 2; But prescription is: Radix Bupleuri 9 grams, the Radix Paeoniae Alba 9 grams, Radix Pseudostellariae 6 grams, Radix Glycyrrhizae 6 grams, the Rhizoma Atractylodis Macrocephalae 9 grams, Poria 9 grams.
Embodiment 20, and is basic identical with embodiment 1 or 2, but write out a prescription is: Radix Bupleuri 9 grams, and the Radix Paeoniae Alba 9 grams, Radix Pseudostellariae 6 grams, Radix Glycyrrhizae 6 restrain, Cortex Albiziae 9 restrains,
Embodiment 21, and is basic identical with embodiment 1 or 2, but prescription is: Radix Bupleuri 9 grams, the Radix Paeoniae Alba 9 grams, Radix Pseudostellariae 6 grams, Radix Glycyrrhizae 6 grams, Fructus Aurantii Immaturus 6 grams.
Embodiment 22, and is basic identical with embodiment 1 or 2, but prescription is: Radix Bupleuri 9 grams, the Radix Paeoniae Alba 9 grams, Radix Pseudostellariae 6 grams, Radix Glycyrrhizae 6 grams, Poria 9, the Rhizoma Atractylodis Macrocephalae 9 grams.
Embodiment 23, and is basic identical with embodiment 1 or 2, but prescription is: Radix Bupleuri 9 grams, the Radix Paeoniae Alba 9 grams, Radix Pseudostellariae 6 grams, Radix Glycyrrhizae 6 grams, Rhizoma Chuanxiong 6 grams.
Embodiment 24, and is basic identical with embodiment 1 or 2, but prescription is: Radix Bupleuri 9 grams, the Radix Paeoniae Alba 9 grams, Radix Pseudostellariae 6 grams, the Rhizoma Atractylodis Macrocephalae 9 grams, Radix Glycyrrhizae 6 grams, Fructus Aurantii Immaturus 6 grams.
Embodiment 25, and is basic identical with embodiment 1 or 2, but prescription is: Radix Bupleuri 9 grams, the Radix Paeoniae Alba 9 grams, Radix Pseudostellariae 6 grams, Radix Glycyrrhizae 6 grams, the Rhizoma Atractylodis Macrocephalae 9 grams, Rhizoma Coptidis 6-9 gram.
Embodiment 26, and is basic identical with embodiment 1 or 2, but prescription is: Radix Bupleuri 9 grams, the Radix Paeoniae Alba 9 grams, Radix Pseudostellariae 6 grams, Radix Glycyrrhizae 6 grams, Pericarpium Citri Reticulatae 6 grams, Fructus Aurantii Immaturus 6 grams.
Embodiment 27, and is basic identical with embodiment 1 or 2, but prescription is: Radix Bupleuri 9 grams, the Radix Paeoniae Alba 9 grams, Radix Pseudostellariae 6 grams, the Rhizoma Atractylodis Macrocephalae 9 grams, Radix Glycyrrhizae 6 grams, Rhizoma Coptidis 6 grams, Pericarpium Citri Reticulatae 6 grams.
Embodiment 28, and is basic identical with embodiment 1 or 2, but prescription is: Radix Bupleuri 9 grams, the Radix Paeoniae Alba 9 grams, Radix Pseudostellariae 6 grams, the Rhizoma Atractylodis Macrocephalae 9 grams, Radix Glycyrrhizae 6 grams, Radix Saposhnikoviae 9 grams.
Embodiment 29, and is basic identical with embodiment 1 or 2, but prescription is: Radix Bupleuri 9 grams, the Radix Paeoniae Alba 9 grams, Radix Pseudostellariae 6 grams, the Rhizoma Atractylodis Macrocephalae 9 grams, Radix Glycyrrhizae 6 grams, Rhizoma Chuanxiong 6 grams.
Embodiment 30, and is basic identical with embodiment 1 or 2, but prescription is: Radix Bupleuri 9 grams, the Radix Paeoniae Alba 9 grams, Radix Pseudostellariae 6 grams, the Rhizoma Atractylodis Macrocephalae 9 grams, Radix Glycyrrhizae 6 grams, Radix Angelicae Sinensis, Rhizoma Coptidis 3 grams.
Embodiment 31, and is basic identical with embodiment 1 or 2, but prescription is: the Rhizoma Atractylodis Macrocephalae 9 grams, Poria 9 grams, Radix Glycyrrhizae 6 grams, Radix Bupleuri 6 grams, Radix Pseudostellariae 6 grams, the Radix Paeoniae Alba 12 grams, Radix Scutellariae 9 grams.
Embodiment 32, and is basic identical with embodiment 1 or 2, but prescription is: Radix Bupleuri 9 grams, the Radix Paeoniae Alba 9 grams, Radix Pseudostellariae 6 grams, the Rhizoma Atractylodis Macrocephalae 9 grams, Radix Glycyrrhizae 6 grams.
Embodiment 33, and is basic identical with embodiment 1 or 2, but prescription is: Radix Bupleuri 9 grams, the Radix Paeoniae Alba 9 grams, Radix Pseudostellariae 6 grams, the Rhizoma Atractylodis Macrocephalae 9 grams, Radix Glycyrrhizae 6 grams, Rhizoma Chuanxiong 6 grams, Poria 9 grams.
Embodiment 34, and is basic identical with embodiment 1 or 2, but prescription is: Radix Bupleuri 9 grams, the Radix Paeoniae Alba 9 grams, Radix Pseudostellariae 6 grams, Radix Glycyrrhizae 6 grams.
With reference to Fig. 1, Fig. 2: above-mentioned composition is adopted water, ethanol or other organic solvent extraction;
Purifies and separates drying: aqueous extract, vacuum concentration, ethanol precipitation, resin absorption, resins exchange, high speed centrifugation, the extract that methods such as spray drying, vacuum drying, cyclodextrin inclusion compound obtain;
Adding is by the water of the Rhizoma Atractylodis Macrocephalae 9 grams, Rhizoma Chuanxiong 6 grams, Poria 9 grams or the compositions that ethanol extraction obtains.
Above medicine adds granule, capsule, tablet, percutaneous or the mucosal preparation of suitable pharmaceutic adjuvant preparation, the suppository of rectally after crushed.
Embodiment 35, and is basic identical with embodiment 34, but adds by the water of the Rhizoma Atractylodis Macrocephalae 9 grams, Fructus Aurantii Immaturus 9 grams or the compositions that extract obtains.
Embodiment 36, and is basic identical with embodiment 34, but adds by the water of Radix Saposhnikoviae 9 grams, Pericarpium Citri Reticulatae 9 grams or the compositions that extract obtains.
Embodiment 37, and is basic identical with embodiment 34, but adds the water extract by Rhizoma Coptidis, Fructus Aurantii Immaturus.
Embodiment 38, and is basic identical with embodiment 34, but adds by the Rhizoma Atractylodis Macrocephalae 9 grams, the n-butanol extract of Radix Saposhnikoviae 6-9 gram.
Embodiment 40, and is basic identical with embodiment 34, but adds the ethyl acetate extract by Fructus Aurantii Immaturus 6 grams.
Embodiment 41, and is basic identical with embodiment 34, but adds by Pericarpium Citri Reticulatae 6 grams, the water extract of Fructus Aurantii Immaturus 6 grams.
Embodiment 42, and is basic identical with embodiment 34, but adds the water extract by the Rhizoma Atractylodis Macrocephalae 9 grams, Rhizoma Chuanxiong 6 grams.
Embodiment 43, and is basic identical with embodiment 1 or 2.Radix Bupleuri 9 grams, the Radix Paeoniae Alba 9 grams, Radix Pseudostellariae 6 grams, Radix Glycyrrhizae 6 grams.Above-mentioned composition is adopted water, ethanol or other organic solvent extraction;
Purifies and separates drying: aqueous extract, vacuum concentration, ethanol precipitation, resin absorption, resins exchange, high speed centrifugation, the extract that methods such as spray drying, vacuum drying, cyclodextrin inclusion compound obtain;
Add alosetron (Alosetron) 0.5-3mg,
Above medicine adds granule, capsule, tablet, percutaneous or the mucosal preparation of suitable pharmaceutic adjuvant preparation, the suppository of rectally after crushed.
Embodiment 44, and is basic identical with embodiment 43, but changes alosetron into domperidone (domperidone) 5-20mg.
Embodiment 45, and is basic identical with embodiment 43, changes alosetron into cisapride (cisapride) 1-20mg.
Embodiment 46, and is basic identical with embodiment 43, and alosetron is changed into for adding thiophene sieve (Tegaserod) 2-15mg.
Embodiment 47, and is basic identical with embodiment 43, changes alosetron into otilonium Bromide (Spasmomen) 50-200mg.
Embodiment 48, and is basic identical with embodiment 43, changes alosetron into pinaverium bromide (Pinaverumbromide) 50-200mg.
Embodiment 49, and is basic identical with embodiment 43, changes alosetron into Trimebutine Maleate (Trimebutine) 0.2-1.5g.
Embodiment 50, and is basic identical with embodiment 43, changes alosetron into butyric acid bacteria 40-200mg.
Embodiment 51, Radix Bupleuri 9 gram, and the Radix Paeoniae Alba 9 grams, Radix Pseudostellariae 6 grams, Radix Glycyrrhizae 6 grams, the Rhizoma Atractylodis Macrocephalae 9 grams, after crushed, 54000 grams, ten times of water, 100 ℃ are extracted twice, and each one hour, merge extractive liquid,, concentrating under reduced pressure (50 ℃, 0.1M) to relative density 1.07, add 95% ethanol and make solution contain alcohol amount to be 50%, 4 ℃ and to deposit 24 hours.Get the supernatant spray drying, total solid 8100 grams prepare various solid preparations; Or get supernatant obtaining liq preparation.
Embodiment 52, Radix Bupleuri 9 grams, the Radix Paeoniae Alba 9 grams, Radix Pseudostellariae 6 grams, Radix Glycyrrhizae 6 grams, the Rhizoma Atractylodis Macrocephalae 9 grams are after crushed, 54000 grams, ten times of water, 100 ℃ are extracted twice, each one hour, merge extractive liquid,, successively, behind the cation exchange resin column (strong-acid type), and use PH5 respectively by anion-exchange resin column (weak base type).5 acetate buffer solutions, PH9.0 ammonia buffer solution elution, the eluent concentrating under reduced pressure (50 ℃ ,-0.1M), get total solid 1610 grams behind the vacuum drying, prepare various solid preparations; Or get concentrated solution obtaining liq preparation.
Embodiment 53, Radix Bupleuri 9 grams, the Radix Paeoniae Alba 9 grams, Radix Pseudostellariae 6 grams, Radix Glycyrrhizae 6 grams, the Rhizoma Atractylodis Macrocephalae 9 restrain after crushed, and 54000 grams extract twice, each ten times of water for 100 ℃, one hour, merge extractive liquid, was successively by behind the macropore exchange resin column (AB-8), and use 20%, 40%, 60% respectively, 95% alcoholic solution eluting, the eluent concentrating under reduced pressure (50 ℃ ,-0.1Mpa), total solid 1730 grams behind the vacuum drying prepare various solid preparations; Or get concentrated solution obtaining liq preparation.
Embodiment 54, Radix Bupleuri 9 grams, the Radix Paeoniae Alba 9 grams, Radix Pseudostellariae 6 grams, Radix Glycyrrhizae 6 grams, the Rhizoma Atractylodis Macrocephalae 9 grams are after crushed, 54000 grams extract twice, each ten times of water, one hour for 100 ℃, merge extractive liquid,, concentrating under reduced pressure (50 ℃ ,-0.1Mpa) to relative density 1.07-1.10, the centrifugal 20min of 4000~20000rpm, get total solid 10220 grams after getting the supernatant spray drying, prepare various solid preparations; Or get supernatant obtaining liq preparation.
Embodiment 55, with reference to Fig. 1, Fig. 2: Radix Bupleuri 9 grams, the Radix Paeoniae Alba 9 grams, Radix Pseudostellariae 6 grams, Radix Glycyrrhizae 6 grams, the Rhizoma Atractylodis Macrocephalae 9 grams are after crushed, 54000 grams extract twice, each ten times of water, one hour for 100 ℃, merge extractive liquid,, concentrating under reduced pressure (50 ℃ ,-0.1Mpa) to relative density 1.07-1.10,4000~20000rpm, 20min gets the ultrafilter membrane of supernatant by 50000M or 10000M.Get the ultrafiltrate concentrating under reduced pressure (50 ℃ ,-0.1Mpa), after the spray drying total solid 7030 is restrained and is equipped with various solid preparations; Or get ultrafiltrate and prepare injection.
Embodiment 56, Radix Bupleuri 9 grams, the Radix Paeoniae Alba 9 grams, Radix Pseudostellariae 6 grams, Radix Glycyrrhizae 6 grams, the Rhizoma Atractylodis Macrocephalae 9 restrain after crushed, and 54000 grams extract twice, each ten times of water for 100 ℃, one hour, merge extractive liquid,, (50 ℃ of concentrating under reduced pressure,-0.1Mpa) to relative density 1.35-1.40, add a small amount of silica gel and mix, adopt silicagel column, 20%, 40%, 60%, 95% alcoholic solution stepwise elution, (50 ℃ of each section eluent difference concentrating under reduced pressure,-0.1Mpa), obtain 130 grams behind the vacuum drying respectively, 320 grams, 570 grams, 598 gram solid contents prepare various solid preparations; Or get concentrated solution obtaining liq preparation.
Embodiment 57, Radix Bupleuri 9 grams, the Radix Paeoniae Alba 9 grams, Radix Pseudostellariae 6 grams, Radix Glycyrrhizae 6 grams, the Rhizoma Atractylodis Macrocephalae 54000 grams are after being ground into coarse granule, add ten times of water, water vapour distillation 5 hours is collected distillate, merge, in distillate, add Sal and make saturatedly, placed 24 hours, separate grease 25 and restrain, add 200 gram beta-schardinger dextrin-s, use milling treatment of colloid 30 minutes.Vacuum drying (50 ℃ ,-0.1Mpa).Obtain white solid 206 grams, prepare various solid preparations.
Embodiment 58, are raw material with basic side, get extract E and component as medicine: the Chinese medicine compound compositions adopts water extraction, after suitably concentrating, adds Different concentrations of alcohol, and is centrifugal after leaving standstill, and gets supernatant concentration, obtains.Through HPLC, TLC, IR, NHR, MS, analyses such as UV wherein mainly contain composition combination two, three, four, five, six.The total solid yield is the 14-18% of medical material weight.
Embodiment 59, with basic side is raw material, get extract S and component as medicine: the Chinese medicine compound compositions adopts water extraction, after suitably concentrating, through silicagel column repeatedly chromatography obtain the different composition combination of a plurality of polarity respectively, through HPLC, TLC, IR, NHR, MS, analyses such as UV are respectively composition combination two, three, four, five, six, seven.
Embodiment 60, are raw material with basic side, get extract L and component as medicine: the Chinese medicine compound compositions adopts water extraction, obtains a plurality of different compositions combinations through ion exchange column exchange absorption.Through HPLC, TLC, IR, NHR, MS, analyses such as UV wherein are respectively composition combination two, three, four, five.
Embodiment 61, are raw material with basic side, get extract G and component as medicine: the Chinese medicine compound compositions adopts water extraction, after suitably concentrating, and after the high speed centrifugation processing, the component of water-soluble solution.Obtain a plurality of different compositions combinations.Through HPLC, TLC, IR, NHR, MS, analyses such as UV wherein are respectively composition combination two, three, four, five.The total solid yield is the 18-24% of medical material weight.
Embodiment 62, are raw material with basic side, get extract D and component as medicine: the Chinese medicine compound compositions adopts water extraction, and eluting obtains a plurality of different compositions combinations behind absorption with macroporous adsorbent resin.Through HPLC, TLC, IR, NHR, MS, analyses such as UV wherein are respectively composition combination two, three, four, five, six, seven.The solid yield is the 2.0-7.0% of medical material weight.
Embodiment 63, with basic side is raw material, get extract C and component as medicine: the Chinese medicine compound compositions adopts water extraction, after suitably concentrating, through high speed centrifugation, obtain different composition combinations after the hyperfiltration treatment, through HPLC, TLC, IR, NHR, MS, analyses such as UV wherein are respectively composition combination two, three, four, five, six, seven.The total solid yield is the 10-15% of medical material weight.
Claims (10)
1, a kind of Chinese medicine composition for the treatment of bowel dysfunction comprises following component:
Radix Bupleuri 6-18 gram,
Radix Paeoniae Alba 6-30 gram,
Radix Pseudostellariae 6-18 gram,
Radix Glycyrrhizae 6-15 gram.
2, according to the Chinese medicine composition of the described treatment bowel dysfunction of claim 1, it is characterized in that: described each component be with extract as medicine, said extract is meant:
A, extraction volatile oil for backup from above mentioned compound;
B, the compositions behind the said extracted volatile oil is adopted water, ethanol or other organic solvent extraction;
Compositions behind c, water, ethanol or other organic solvent extraction adopts vacuum concentration, ethanol precipitation, resin absorption, resins exchange, high speed centrifugation, the extract that methods such as cyclodextrin inclusion compound obtain;
D, the extract of above steps is merged, become pharmaceutical composition.
3, according to the Chinese medicine composition of the described treatment bowel dysfunction of claim 2, it is characterized in that: the ratio of described each component as the extract raw material is:
Radix Bupleuri 12-18 gram,
Radix Paeoniae Alba 12-30 gram,
Radix Pseudostellariae 6-12 gram,
Radix Glycyrrhizae 6-12 gram,
Or:
Radix Bupleuri 9-12 gram,
Radix Paeoniae Alba 9-12 gram,
Radix Pseudostellariae 6-12 gram,
Radix Glycyrrhizae 6-12 gram.
4, according to the Chinese medicine composition of claim 2 or 3 described treatment bowel dysfunctions, it is characterized in that: said Chinese medicine composition extract is meant a kind of in the following combination,
Extract E and component: the Chinese medicine compound compositions adopts water extraction, after suitably concentrating, adds Different concentrations of alcohol, and is centrifugal after leaving standstill, and gets supernatant concentration, obtains; Or
Extract S and component: the Chinese medicine compound compositions adopts water extraction, after suitably concentrating, through silicagel column repeatedly chromatography obtain the different composition of a plurality of polarity respectively and make up; Or
Extract L and component: the Chinese medicine compound compositions adopts water extraction, obtains a plurality of different compositions combinations through ion exchange column exchange absorption; Or
Extract G and component: the Chinese medicine compound compositions adopts water extraction, after suitably concentrating, and after high speed centrifugation is handled, the component of water-soluble solution.Obtain a plurality of different compositions combinations; Or
Extract D and component: the Chinese medicine compound compositions adopts water extraction, and eluting obtains a plurality of different compositions combinations behind absorption with macroporous adsorbent resin; Or
Extract C and component: the Chinese medicine compound compositions adopts water extraction, after suitably concentrating, through high speed centrifugation, obtains different composition combinations after the hyperfiltration treatment.
5, according to the Chinese medicine composition of claim 1 or 2 or 3 described treatment bowel dysfunctions, it is characterized in that: also contain flavor of 1 in the following medicine or 2 flavors or 3 flavors: the Rhizoma Atractylodis Macrocephalae 9 grams, Rhizoma Chuanxiong 6 grams, Poria 9 grams, Radix Puerariae 9 grams, Fructus Aurantii Immaturus 6~9 grams, Ramulus Cinnamomi 9 grams, Pericarpium Citri Reticulatae 6~9 grams, Radix Saposhnikoviae 9 grams, Radix Angelicae Sinensis 9 grams, the Rhizoma Pinelliae 9 grams, Rhizoma Coptidis 6~9 grams, Radix Et Rhizoma Rhei 6 grams, Radix Scutellariae 9 grams, Cortex Albiziae 9 grams.
6, according to the Chinese medicine composition of the described treatment bowel dysfunction of claim 5, it is characterized in that: writing out a prescription is one of following combination:
Radix Bupleuri 12 grams, the Radix Paeoniae Alba 12 grams, Radix Pseudostellariae 6 grams, the Rhizoma Atractylodis Macrocephalae 9 grams, Radix Glycyrrhizae 6 grams;
Radix Bupleuri 9 grams, the Radix Paeoniae Alba 9 grams, Radix Pseudostellariae 6 grams, Radix Glycyrrhizae 6 grams, the Rhizoma Atractylodis Macrocephalae 9 grams;
Radix Bupleuri 9 grams, the Radix Paeoniae Alba 9 grams, Radix Pseudostellariae 6 grams, Radix Glycyrrhizae 6 grams, the Rhizoma Atractylodis Macrocephalae 9 grams, Poria 9 grams;
Radix Bupleuri 9 grams, the Radix Paeoniae Alba 9 grams, Radix Pseudostellariae 6 grams, the Rhizoma Atractylodis Macrocephalae 9 grams, Radix Glycyrrhizae 6 grams, Rhizoma Chuanxiong 6 grams;
Radix Bupleuri 9 grams, the Radix Paeoniae Alba 9 grams, Radix Pseudostellariae 6 grams, the Rhizoma Atractylodis Macrocephalae 9 grams, Radix Glycyrrhizae 6 grams, Fructus Aurantii Immaturus 6 grams;
Radix Bupleuri 9 grams, the Radix Paeoniae Alba 9 grams, Radix Pseudostellariae 6 grams, the Rhizoma Atractylodis Macrocephalae 9 grams, Radix Glycyrrhizae 6 grams, Rhizoma Chuanxiong 6 grams, Poria 9 grams.
7, according to the Chinese medicine composition of claim 5 or 6 described treatment bowel dysfunctions, it is characterized in that: the described Rhizoma Atractylodis Macrocephalae, Rhizoma Chuanxiong, Poria, Radix Puerariae, Fructus Aurantii Immaturus, Ramulus Cinnamomi, Pericarpium Citri Reticulatae, Radix Saposhnikoviae, Radix Angelicae Sinensis, the Rhizoma Pinelliae, Rhizoma Coptidis, Radix Et Rhizoma Rhei, Radix Scutellariae, Cortex Albiziae are the assemblys of extract, a kind of and multiple extract or chemical constituent that adopts water, ethanol or the organic solvent of its a kind of and multiple medicine, or the extract combination body of the extract of a kind of and multiple different pharmaceutical combination after making up once more.
8, according to the Chinese medicine composition of claim 1 or 2 or 3 described treatment bowel dysfunctions, it is characterized in that, also contain a kind in the following medicine: dioctahedral smectite 2-10g, domperidone 5-20mg, cisapride 1-20mg, for adding thiophene sieve 2-15mg, alosetron 0.5-3mg, otilonium Bromide 50-200mg, pinaverium bromide 50-200mg, Trimebutine Maleate 0.2-1.5g, butyric acid bacteria 40-200mg.
9, the preparation method of the described treatment bowel dysfunction of one of a kind of claim 1~8 Chinese medicine composition, step is as follows:
Above-mentioned composition is adopted water, ethanol or other organic solvent extraction;
Compositions behind above-mentioned water, ethanol or other organic solvent extraction is adopted one or more purifies and separates of following method: vacuum concentration, ethanol precipitation, resin absorption, resins exchange, high speed centrifugation, methods such as cyclodextrin inclusion compound obtain extract;
Above extract merges, and the direct or purified back of separating adds suitable pharmaceutic adjuvant, is prepared into the suppository of granule, capsule, tablet, oral liquid, parenteralia, percutaneous or mucosal preparation, rectally respectively; Or above medicine adds granule, capsule, tablet, percutaneous or the mucosal preparation of suitable pharmaceutic adjuvant preparation, the suppository of rectally after crushed.
10, according to the preparation method of the described treatment bowel dysfunction of claim 9 Chinese medicine composition, it is characterized in that, also be provided with following steps:
Above-mentioned composition is adopted water, ethanol or other organic solvent extraction; Obtain containing the position of above-mentioned chemical constituent assemblage characteristic respectively,
Or the combination once more at these positions;
Or also be provided with following steps: after above-mentioned composition is adopted water, ethanol extraction, utilize vacuum concentration, ethanol precipitation or resin absorption or resins exchange or high speed centrifugation, or method for purifying and separating such as cyclodextrin inclusion compound obtains containing above Chemical composition that Feature Extraction thing; Or these extracts make up once more.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200410014337 CN1579485B (en) | 2004-03-16 | 2004-03-16 | Traditional Chinese medicinal composition for treating intestinal function disorder and its preparation method |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200410014337 CN1579485B (en) | 2004-03-16 | 2004-03-16 | Traditional Chinese medicinal composition for treating intestinal function disorder and its preparation method |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1579485A true CN1579485A (en) | 2005-02-16 |
CN1579485B CN1579485B (en) | 2010-04-28 |
Family
ID=34581704
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 200410014337 Expired - Fee Related CN1579485B (en) | 2004-03-16 | 2004-03-16 | Traditional Chinese medicinal composition for treating intestinal function disorder and its preparation method |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1579485B (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010133015A1 (en) * | 2009-05-21 | 2010-11-25 | 陈婷 | Pharmaceutical composition for treating depression and preparative method and use thereof |
CN101199639B (en) * | 2007-12-20 | 2011-12-14 | 北京天力正元医药技术开发有限公司 | Chinese medicine for treating irritable |
CN101700289B (en) * | 2009-11-02 | 2012-02-15 | 南京师范大学 | Traditional Chinese medicine extract composition for treating gastrointestinal dysfunction or irritable bowel syndrome (IBS), and preparation method and applications thereof in preparation of medicaments |
CN104248666A (en) * | 2009-03-13 | 2014-12-31 | Cj医药健康株式会社 | Compositions for preventing or improving gastrointestinal diseases |
CN104984002B (en) * | 2015-06-16 | 2018-05-29 | 成都乾坤动物药业有限公司 | A kind of multi-functional Chinese and western medicinal composition for animals and preparation method thereof |
-
2004
- 2004-03-16 CN CN 200410014337 patent/CN1579485B/en not_active Expired - Fee Related
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101199639B (en) * | 2007-12-20 | 2011-12-14 | 北京天力正元医药技术开发有限公司 | Chinese medicine for treating irritable |
CN104248666A (en) * | 2009-03-13 | 2014-12-31 | Cj医药健康株式会社 | Compositions for preventing or improving gastrointestinal diseases |
WO2010133015A1 (en) * | 2009-05-21 | 2010-11-25 | 陈婷 | Pharmaceutical composition for treating depression and preparative method and use thereof |
CN102438630A (en) * | 2009-05-21 | 2012-05-02 | 张作光 | Pharmaceutical composition for treating depression and preparative method and use thereof |
CN101700289B (en) * | 2009-11-02 | 2012-02-15 | 南京师范大学 | Traditional Chinese medicine extract composition for treating gastrointestinal dysfunction or irritable bowel syndrome (IBS), and preparation method and applications thereof in preparation of medicaments |
CN104984002B (en) * | 2015-06-16 | 2018-05-29 | 成都乾坤动物药业有限公司 | A kind of multi-functional Chinese and western medicinal composition for animals and preparation method thereof |
Also Published As
Publication number | Publication date |
---|---|
CN1579485B (en) | 2010-04-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1748765A (en) | Composition with catharsis and toxin expelling, fat reducing and weight reducing function and preparing method | |
CN1778383A (en) | Herbal medical preparation for the treatment of arthritis | |
CN1954840A (en) | Medical composite prepared by Gynostemma pentaphylla, American ginseng and astragalus root | |
CN1799613A (en) | Chinese medicine for treating damp heat arthralgia and its preparation method | |
CN1712048A (en) | Chinese medicines for stomach pain due to Qi stagnation and its preparing method | |
CN1663597A (en) | Qi-invigorating, blood-nourishing medicinal composition and its preparing method | |
CN1245198C (en) | Chinese medicine composition for treating diabetes and its preparing method | |
CN101062084A (en) | Anti-hepatitis medical combination | |
CN1559519A (en) | Prunella spike extract and its preparation method and use | |
CN1957999A (en) | Composition of Chinese traditional medicine, preparation method, and quality control method | |
CN1895438A (en) | Chinese-medicinal composition for treating cephalagia and its preparation | |
CN1923241A (en) | Medicine composition containing epimedium extract, uncaria extract, and gastrodine, and its preparation and use | |
CN1947747A (en) | Traditional Chinese medicine composition contg. luteolin and capsule of sweeping forsythia and its prepn. method and use | |
CN1579485A (en) | Traditional Chinese medicinal composition for treating intestinal function disorder and its preparation method | |
CN1201805C (en) | Combination of medication for reducing poison and synergic action in radiotherapy or chemotherapy as well as its preparing method | |
CN100341492C (en) | Ginseng-astragalus blood-sugar lowering soft capsule, and its preparing and detecting method | |
CN1954849A (en) | Antineoplastic medical composite compatibility with oldenlandia, ginseng and astragalus root | |
CN1064550C (en) | Drug for curing premenstrual tension | |
CN1579455A (en) | Composition of traditional Chinese medicine for large intestine hygropyretic disease and its preparation method | |
CN1294936C (en) | Medicine for treating diabetes and its preparation method | |
CN1112439A (en) | Chinese medicine for diabetes and its preparation | |
CN1931233A (en) | Medicine composition of red sage and epimedium for treating cardiac and cerebral vascular diseases | |
CN1650996A (en) | Medicinal composition, its preparation method and application | |
CN1709436A (en) | Yinzhihuang tablet of oriental wormwood, cape jasmine and baicalin, and its preparing and detecting method | |
CN1562144A (en) | Chinese medicinal composition for treating intestine irritable syndrome and its preparing method |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C17 | Cessation of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20100428 Termination date: 20140316 |